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It is easy to become overwhelmed by the statistics on
HIV/AIDS. In 2004, another 5 million people became
infected with HIV, bringing the total number of people with
HIV to 40 million. All of these people – like 3 million others
this year – will die with AIDS, a death that can only be
delayed with drugs that remain available only to the very
few.
There is, however, some good news. According to
UNAIDS, global funding for the battle against HIV is up –
reaching US$ 6.1 billion. AIDS education is reaching
nearly three-times more secondary school students, and
the number of people receiving voluntary counselling and
testing services has doubled over the last two years.
440,000 people are on anti-retroviral (ARV) therapy. 
These efforts, however, are simply not enough to contain
the pandemic or to reach those in need. Less than 1% of
adults aged 15 to 49 access voluntary counselling and
testing. Fewer than one in 10 pregnant women are
offered services to prevent HIV transmission to their
children. The number of people getting ARVs is only
about 10% of those who would benefit from it. Another
14,500 people are infected with HIV each and every day.
Ever more children swell the numbers – over 10 million –
of orphans. 
So what does this report, based on the second global
survey of the business response to HIV and conducted by
the Global Health Initiative of the World Economic Forum,
tell us about what business is doing as the communities
around them are being slowly eroded? Again, there is
some good news, and some discouraging news. Overall,
it seems that more companies have enacted policies and
are running programmes to combat HIV. Even in countries
with the highest rates of HIV (greater than 20% adult
prevalence), however, more than one-quarter of
companies have not done so. In other words, overall,
businesses are still not doing enough.
The world is expecting more and more of its corporate
citizens, while heightened international competition means
that investors are increasingly demanding of results. What
is needed – and not only to enhance companies’ actions
against HIV – is for managers and investors to place a
premium on long-term value creation, a fundamental
underpinning of corporate social responsibility. Executives
should consider activities that build the capacity and well-
being of their workforces as investments for future
productivity rather than current costs. Investors should
increasingly ask companies in their prospective or current
portfolios what they are doing about HIV. Then they
should ask for more.
The numbers concerning HIV are not encouraging. It is
impossible to comprehend the individual stories that they
represent. Global leaders from all walks of society must
do more. We hope that this year’s report will move many
others to greater commitment and action. 
Klaus Schwab, 
Founder and Executive
Chairman, World
Economic Forum
In the face of a worsening epidemic it seems
extraordinary that business leaders are less concerned
about HIV/AIDS in 2004-5 than they were in 2003-4. I
fear that this decreasing concern is for all the wrong
reasons – including complacency, ignorance, denial. No
doubt business leaders perceive that there are more
urgent and immediate business problems to deal with; it
will take decades for the full global impact of AIDS to
materialize. HIV/AIDS is someone else’s problem –
something the government or the United Nations must
sort out.
HIV is a very smart virus. It attacks human weakness, both
biological and behavioural. It targets the core of our
human defences – the immune system. It infiltrates
through the most secret route – our human sexuality and
sexual behaviour. It exploits the power imbalance of
human gender and exposes the weakness of relationships
in our society. Unlike SARS, it is covert and insidious in its
operation, taking an average of 8 to 10 years before
manifesting as a disease with 100% mortality. Humans are
quite complacent about small changes over a long period
of time. We are much more adept at responding to crises
than planning for the long term. That is why SARS failed
and HIV continues to thrive.
So perhaps it is not surprising to note the disappointing
global business response to HIV/AIDS. It is merely in line
with the rest of the world’s response over the past 20
years – too little, too late. Left unchecked, this is why HIV
will succeed in becoming the greatest killer in human
history. The insidious, but compounding, negative effect
of HIV/AIDS on global economic growth will only be
revealed to future generations. Meanwhile HIV will thrive
on poverty – “… a disease that creates the conditions
that favour its spread is the most dangerous disease of
all.” (The New Face of AIDS; The Economist; 25
November 2004.)
However, there are lessons that have been learned from
the countries worst affected by HIV/AIDS. It is not
surprising to note that firms in these countries are not
only the most concerned, but are also driving the most
effective responses.
Today we know the urgent importance of getting HIV
prevention messages to young people and of nurturing
healthy sexuality. We are shocked at the extraordinary
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vulnerability of young women to HIV infection and the
disproportionate impact of the epidemic on them – we
must respond with everything we have got to protect them.
We have learned about the profound effect of migrancy on
the spread of HIV. It may be an unavoidable feature of the
economic systems of many developing countries, but it
can no longer be business as usual. New and innovative
ways to ensure the integrity of families must be pursued.
The debate is no longer about the merits of prevention
versus testing, treatment and care. We now understand
that all of these are needed on a much greater scale than
anything achieved to date.
We are responding to the urgent need to scale up
voluntary counselling and testing (VCT) for HIV massively.
VCT is the entry point for a continuum of prevention and
care. Firms with successful HIV/AIDS programmes are
reporting VCT uptake in excess of 75% of the workforce.
We need a complete change in approach – knowing your
HIV status should become as routine as knowing your
blood pressure or your cholesterol level.
Access to simple and effective anti-retroviral treatment
has profoundly changed the course of the AIDS epidemic.
It is the most effective weapon for banishing fear and
ignorance and for preventing stigma and discrimination.
Today AIDS can be managed as a chronic disease. With
early access to effective treatment, there will be no
opportunistic infections, very little absenteeism, no loss of
productivity and little need for hospital or home-based
care. The economics of providing access to treatment in
the workplace are self-evident.
Today we know that those firms that respond to HIV/AIDS
with strong leadership at the CEO level, impact
assessments based on real data, negotiated HIV/AIDS
policies, up-to-date strategic HIV/AIDS responses,
specific HIV/AIDS performance indicators and targets,
and ongoing monitoring and evaluation also happen to
show the greatest productivity, the most effective cost
containment and the greatest profitability. These firms are
also invariably the safest, the most environmentally
responsible and the most harmonious with the
communities within which they operate. In short, a good
response to HIV/AIDS is synonymous with good
management, good business and a good investment.
There is indeed cause for optimism – outstanding
technological advances in testing and treatment; knowing
what needs to be done and how to do it; improved global
funding and tremendous opportunities for public private
partnerships in response to HIV/AIDS. If these are the
reasons for a reduced business concern about HIV/AIDS
in 2004-5, coupled with a positive commitment for action,
then we would indeed have cause to celebrate.
P r e f a c e  
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It is time that global corporations heed a wake-up call on
the HIV/AIDS issue. Examine the approach that the
majority of companies adopt in this arena. HIV/AIDS is
placed firmly in the Corporate Social Responsibility (CSR)
“box”, a safe and secure place for any marginally difficult
corporate or social issue to be parked. And to be fair,
HIV/AIDS is more than just marginally difficult. Too many
companies seem to be saying to themselves and their
stakeholders, “Well, there’s a problem out there, and we
want to be seen to be doing the ‘right’ thing.”
About 80% of global economic output is produced by the
G-8 countries. These countries are home to the world’s
most powerful, influential and profitable corporations.
Almost without exception, the problem of HIV/AIDS is
thought of as existing elsewhere, in underdeveloped and
developing countries. Consequently, most corporations
belonging to and in the “rich” eight exhibit a lack of
concern or urgency. A distant problem is easily ignored,
particularly when the critical issues for corporations are
driven by the visceral reactions of capital markets and
investors focused on short- and medium-term returns. 
Let’s, however, try to put this issue in a slightly different
perspective. It is perhaps somewhat inconvenient that the
countries most impacted by HIV/AIDS represent the
future workforce of the world. Manpower’s research into
the future “world of work” predicts an absolute necessity
for corporations to move sites of operations from the G-8
to a variety of global locations. The G-8 countries have
not had a positive fertility rate for many years, and – short
of the unlikely possibility of democratic governments
imposing a 3 child requirement upon couples – the
problem of a shrinking workforce will worsen over time.
The answer to this problem seems clear: move the work
to countries that have an ample supply of children today
and workers tomorrow. Unfortunately, the most fertile
countries in the world are also – by and large – relatively
poorer countries. But here comes the catch, it is these
countries that are most afflicted by HIV/AIDS.
Solving and alleviating the problem of HIV/AIDS is not just
the responsibility of the United Nations, non-governmental
organizations, or even country governments. Large
corporations garner huge profits from the global
production and distribution of their products. With these
benefits comes a concomitant involvement in and
responsibility to those countries in which companies do
business. There are both moral and economic
justifications for large companies to invest in the
sustained development and delivery of solutions to the
myriad challenges posed by HIV/AIDS. A passive
corporate stance on HIV/AIDS is unacceptable and
should be a passport to global marginalization by both
customers and shareholders. It’s time for corporations to
give more back to the world from which they benefit. How
better to do so than by supporting programmes with
those things businesses have in abundance – things that
the battle against HIV/AIDS so desperately needs: money,
infrastructure, equipment and very talented people?
We require a new global alliance – with business actively
participating – to galvanize greater action against this
worsening pandemic. We need to get the issue of
HIV/AIDS out of the CSR “box” and place it firmly in the
“economic imperative” arena.
The world needs its business leaders to wake up – with
not a moment to lose.
David Arkless, 
Senior Vice-President,
Corporate Affairs, Manpower
Around the world, 40 million people are infected with HIV. In
2004 alone, approximately 5 million people became infected
and 3 million died of the disease. Two billion people are
known to carry tuberculosis (TB), and 3 million died of the
disease during the past year. HIV and TB share the
characteristic of being most common in 15-49 year olds –
people in their productive and reproductive primes. Malaria
kills more than a million people a year, predominantly women
and children. Beyond the social tolls each disease imposes
on developing countries, they individually and jointly pose
significant threats to many nations’ economic growth.
Many firms believe HIV/AIDS, in particular, poses a threat to
their business and that the threat is likely to increase in the
future. Worldwide, 42% of firms report some current or
future impact from the disease, and few believe they or their
workforces will be immune if the epidemic hits their
community. In countries where infection rates are above
10%, nearly two-thirds of firms expect future business
impacts to be serious. Larger firms (those with more than
fifty employees) are more concerned than smaller firms by
HIV.
Business leaders report slightly less concern in 2004-2005
than they did in the 2003-2004 Executive Opinion Survey.
This decline may be due to a number of factors, but if it
becomes a long-term trend and the epidemic continues to
worsen, it presents a considerable challenge to efforts to
raise awareness among businesses and galvanize more
vigorous action.
Although many executives believe HIV/AIDS will affect
aspects of their business, 42% of concerned firms cannot
specify which aspects, if any, are affected. Few firms, even
in the hardest hit regions, have carried out quantitative
HIV/AIDS risk assessments and most do not know
employee infection rates. Most assumptions about the
threats posed by the disease, therefore, are based on
conjecture.
This lack of clarity appears to translate into low levels of
activity in response to HIV. Except in the hardest hit
countries, informal policies outweigh formal ones. Informal
policies, moreover, are less comprehensive in scope than
E x e c u t i v e  S u m m a r y
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This report provides an overview and
summary of business perceptions and
responses to HIV/AIDS. It draws in particular
on the information collected by the 2004-
2005 Executive Opinion Survey that forms
part of the World Economic Forum’s annual
Global Competitiveness Report.
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Business responses vary by region
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formal programmes. In the hardest hit countries, formal
policies are generally limited to those firms that have
conducted formal risk assessments. Conversely, firms
that are unaware of or that have not quantified the likely
impacts of the disease tend not to develop a strategic
response. It is not clear whether quantitative studies spur
some firms to action, or whether firms that are already
concerned and likely to act conduct studies to support
their programmes. If the former is true, it may be that
some firms in high-prevalence settings that have not
conducted studies would respond with urgency similar to
that of their better informed peers if they had greater
knowledge of the risks.
Although more firms have formal HIV/AIDS policies this
year than last, confidence in these policies is mixed. A
(small) majority of firms (51%) is strongly confident in
policies in countries with an HIV prevalence below 1%. In
settings with prevalences between 1% and 19%, less
than one-third of firms with policies are strongly confident.
Surprisingly, in countries with prevalence above 20%,
more firms (39%) report strong confidence, although the
reasons for this are unclear. 
Key Findings
Business leaders are slightly less concerned about
HIV/AIDS than a year ago
• Globally, 30% of executives report some current
impacts on their business from HIV/AIDS, and 37%
expect an impact within the next five years. 
• This concern is lower than in the 2003-2004 survey –
16% expect serious impacts on their business this year,
compared to 21% last year. Even in sub-Saharan Africa,
the epicentre of the epidemic, respondents in 15 of 17
countries report decreased concerns. The reasons for
this are unclear. 
• In low-income countries and countries where HIV
prevalences are high, concern about the impact of
HIV/AIDS on firms is greater, although here, too,
respondents are less worried than a year ago. Where
national prevalence rates are above 10%, almost two-
thirds of respondents expect serious future effects.
Regionally, businesses in sub-Saharan Africa are most
concerned, across all sectors 
• 41% of African firms report serious current impacts on
their business and the majority note negative effects on
operating costs. 
• Firms in the Caribbean are also very concerned, and
they believe the disease’s future impacts (29% are
seriously concerned) will significantly outweigh its
current effects (21%).
• There is little variation in concern about HIV/AIDS
across different industrial sectors. Larger firms,
however, are more concerned than smaller firms.
Business leaders believe the effects on their companies
are linked to the effects on their communities
• Overall, respondents believe their firms will be slightly
less impacted by the epidemic than their surrounding
communities. 
• In countries suffering the most serious epidemics, firms
believe the effects on their communities and their
business will be similarly serious.
HIV/AIDS is seen as a greater threat than malaria and
tuberculosis (TB)
• HIV/AIDS is seen as a more serious threat than either
malaria or TB, both to the firm and community. Even in
countries where concern about malaria is greatest,
HIV/AIDS is seen as the principal infectious disease
threat for the future.
Business leaders rarely have a robust fact base on which
to base decisions…
• Respondents find it difficult to estimate how many of
their employees are HIV-positive, with two-thirds unable
to provide any estimate.
• Estimates of workforce HIV prevalence, when made,
are generally lower than likely infection rates in a
business’s surrounding community. This may be an
accurate reflection of infection rates among those
employed by firms covered in this survey, or may reflect
business uncertainty about workforce prevalence rates.
…even about how HIV is affecting their operations
• Although they are concerned about HIV/AIDS,
executives find it difficult to pinpoint which areas of their
business are affected. Globally, only 1 firm in 20 reports
serious impacts on costs, productivity or revenues. By
contrast, in countries with the most serious epidemics,
around 20% report serious impacts on operating costs.
• Only 14% of firms have conducted quantitative
HIV/AIDS risk assessments. Even in countries with the
most serious epidemics, less than one-third of firms
have carried out such analyses.
Many firms in the hardest hit countries have nevertheless
begun to tackle the epidemic
• In the hardest hit countries, the proportion of firms with
written policies to tackle HIV/AIDS has increased by
75% since 2003-2004, bringing to 72% the percentage
of firms that have a policy, compared to 15% in
countries with the least advanced epidemics. 
• Globally, informal policies (reported by 12% of firms)
outnumber written policies (7%). Informal policies are
less comprehensive than formal policies. Even in high-
prevalence settings, about one-third of firms’ policies
are informal.
• Prevention is the focus of HIV/AIDS programmes,
particularly in poorer countries where few companies
have assumed the higher costs and complexities of
providing anti-retroviral therapy and home-based care.
Confidence in policies is mixed
• Only in low HIV prevalence countries are most firms
(51%) strongly confident in their policies. Elsewhere –
with the notable exceptions of hard-hit South Africa and
Namibia – confidence is weak.
• Firms are more confident about their and their
communities’ ability to tackle HIV/AIDS in countries they
believe to be well governed. This repeats the finding
from 2003-2004 that corporate perceptions of good
governance are correlated with faith in an effective
national response to the disease.
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“AIDS is uniquely destructive to economies,
because it kills people in the prime of their
lives.[…] Especially in its early stages, the
epidemic tends to strike urban centres, the
better educated, the elite in leadership and
the most productive members of society.
These deaths leach profits out of
businesses and economies. […] There are
already several examples of the enormous
impact which corporate action can have in
the fight against HIV/AIDS. They exist both
in the workplace, which is one of the most
effective places to educate and reach
people, and in global efforts through
advocacy, in-kind support, engagement
with partners and direct donations.”
Kofi Annan, Secretary-General of the United
Nations, 1 December 2004
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HIV/AIDS continues to have devastating effects in much
of the developing world. The number of people infected
with HIV continues to grow, although the rate of growth is
now slowing. In 2004, 3.1 million died and 4.9 million
were newly infected with the virus (see figure 1). About 40
million people are now estimated to be HIV-positive.
UNAIDS reports that the global response to the disease
has expanded significantly in recent years but notes that,
in Sub-Saharan Africa in particular, governments have so
far been unable to cope with its scale or spread.1
AIDS and Business: Commitment and Action? presents
the findings of the second global survey of business
leaders’ opinions on and responses to the threat of
HIV/AIDS conducted by the Global Health Initiative of the
World Economic Forum. The first report, Business and
HIV/AIDS: Who Me?, was released at the Forum’s Annual
Meeting in January 2004.2 It is also based on a survey of
executives from over 100 countries. This year, nearly
1,000 more firms responded to the questionnaire and,
although the countries involved overlapped substantially,
they were not identical.3
This report presents and analyses data from the Executive
Opinion Survey component of the Forum’s Global
Competitiveness Report. The Executive Opinion Survey
questioned nearly nine thousand business executives in
104 countries. Questions on HIV/AIDS in the 2004-2005
Survey address the perceived impact of the virus (and to
a lesser extent TB and malaria) on workforces and
communities, the effect of HIV on company operations
and revenues, and firms’ response to the disease.
This year’s report does not include an exhaustive review
of the economic effects of HIV/AIDS, TB and malaria, as
presented in Business and HIV/AIDS: Who Me?, which
can be accessed at
www.weforum.org/globalhealth/whome
“…Today we operate in a world where
both business and society as a whole are
threatened by the scourge of HIV/AIDS.
Moral imperatives demand that we see
beyond purely commercial advantage to
combat this disease…”
Nicky Oppenheimer, Chairman of Investments for
De Beers, 1 December 2004
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Figure 1: The HIV/AIDS pandemic continues to worsen
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The Impact of HIV/AIDS
• Many business leaders are concerned about HIV/AIDS.
Even in wealthy, low-prevalence countries, a small
proportion of firms expect the disease to have some
effect on their business. In poorer, high-prevalence
countries, its impact, already noticeable, is expected to
grow over the next five years.
• Despite the concern, however, firms appear to be
largely working in the dark. Only 34% are able to offer
any estimate of their workforce prevalence rates, and
there is uncertainty over which areas of a business will
experience the greatest impacts from the disease.
• Businesses believe that better-run countries will
respond more effectively to the disease.
Respondents were asked to assess the current and future
impacts of malaria, tuberculosis (TB) and HIV/AIDS on
their business. Of the three diseases, HIV/AIDS causes
the most current and future concern (see maps 1-3).
Unlike the other two diseases, moreover, future concerns
about HIV outweigh those about its present impacts,
suggesting that many respondents see HIV/AIDS as a
looming threat.
• HIV/AIDS: 30% of respondents report some current
impact from HIV/AIDS (see table 6), while 37% expect
future impact (table 9). 12% report serious current
impacts.
• Malaria: 22% report some current impact (table 4) and
21% some future impact (table 7). 10% report serious
current impact.
• TB: 24% report some current impact (table 5) and 25%
expect some future impact (table 8). 8% report a
serious current impact.
Map 1: Global concern over current and future impact on
business of HIV/AIDS (% concerned)
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Map 2: Global concern over current and future impact on
business of malaria (% concerned)
Map 3: Global concern over current and future impact on
business of TB (% concerned)
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Figure 2: HIV/AIDS most concerns companies
Firms in poor countries4 and those with high HIV
prevalence rates5 are most concerned about the impact
of all three diseases. 63% of firms in countries with HIV
prevalence above 10% expect serious impacts from the
disease in the next five years, with around one-quarter
expecting serious impacts from TB and malaria. In poor
countries, malaria is currently regarded as a slightly more
serious threat than HIV/AIDS. However, HIV/AIDS is
regarded as the main health threat for the future, even in
countries where malaria is endemic (see figure 2).6
Impacts on communities
Respondents were asked how seriously HIV/AIDS is
currently affecting the communities in which they operate
(table 10). 67% believe impacts on their business are
minimal, whereas only 55% think the same of impacts on
their communities. It appears that some businesses
believe they will be shielded from the worst effects of the
epidemic – a finding borne out by several studies, which
find infection rates to be higher among the poor (who are
less likely to be employed) than the wealthy.7 This
becomes less true, however, as the epidemic worsens,
with respondents feeling their companies and
communities are equally vulnerable to the burden of
serious impacts (see figure 3). Very few respondents (2%)
believe HIV/AIDS will not be a problem for their firm and a
serious problem for their communities.
Impacts on workforce
Respondents find it very difficult to estimate how many of
their employees are HIV-positive (table 11). Two-thirds
say they do not know or provide no response to this
survey question (see figure 4). Firms from high income
countries and countries with serious existing epidemics
are more likely to be able provide an estimate of
workforce infection rates.
Despite having little hard data, 45% of firms believe their
workforce rates are lower than national prevalence rates,
with many respondents answering this question despite
being unable to provide an estimate of workforce
prevalence (see table 11). A comparison between
UNAIDS estimates of HIV prevalence and company-
specific estimates of workforce prevalence provided in the
survey also suggests firms believe employee infection
rates are lower than those in the country as a whole. Only
15% of firms in countries with national prevalence above
20%, for example, estimate firm-level infection rates at
20% or above.
Impacts on operating costs
A large majority of firms indicate that HIV/AIDS is not
currently having a significant impact on operating costs.
Respondents were asked about the virus’s current effect
on five aspects of company operations: death, disability
13
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Figure 3: The fates of companies and their communities are seen as tightly linked
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Figure 4: The majority of firms does not know the HIV prevalence within
their organization
and funeral expenses; medical expenses; productivity and
absenteeism; recruitment and training expenses; and
revenues (tables 16-20). As figure 5 shows, only around 1
in 20 of all firms reports a serious impact in each of the
categories. Around 15-25% report a serious impact in
these categories in countries with the most serious
epidemics. Firms appear to be unable to distinguish
between the impacts on different aspects of their
operations, suggesting their information base in this area
is limited.
Firms that state that HIV/AIDS is having a serious impact
on their business are slightly more likely to report current
impacts on operations. 29% of these respondents report
serious effects on productivity and absenteeism; 25% on
death, disability and funeral expenses; 25% on medical
expenses; 21% on revenues; and 20% on recruitment
and training costs. What is striking is the high number
estimating minimal effects in each category. 30% of those
who are seriously concerned about HIV cannot specify
which aspect of their business the virus is affecting,
suggesting that many of those businesses that regard
HIV/AIDS as a serious problem are unsure as to exactly
how that problem will manifest itself.
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Figure 5: Companies are reporting negative effects from HIV
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Thus, few firms can estimate the impact of HIV based on
their existing business information systems. At the same
time, only 14% of firms worldwide have conducted
specific quantitative HIV/AIDS risk assessments (table 12).
Even in countries with the highest prevalence rates, only
30% of firms have conducted assessments. This
reinforces a picture of widespread business ignorance
about the impact of the epidemic on their operations.
Despite general concern about HIV, even the most
affected businesses continue to base their opinions on a
limited – and possibly insufficient – information base.
The policy environment affects business concerns
One of the strengths of the Executive Opinion Survey is
the broad range of topics it covers, which allows
comparison of responses to HIV/AIDS questions with
attitudes and opinions on other “business” subjects. In
particular, the relationship between perceptions on
governance and concern over HIV/AIDS may be
examined.
The 2003-2004 analysis showed that businesses
considering their societies to be generally well governed
were less concerned by the threat posed by HIV/AIDS.
Government transparency and honesty, effective
institutions, a free media and a focus on poverty reduction
were all thought to help protect firms and communities.
This year, too, confidence in effective institutions and
social equity tend to reduce concern over the impacts of
HIV/AIDS. After accounting for income, region, HIV
prevalence, type of industry and firm size, the following
factors are most influential on perceptions of HIV’s impact
on firms and communities:
• A business-friendly environment. Effective protection of
intellectual property, strong general infrastructure and
good public schools all strengthen confidence about
the impact of HIV/AIDS.
• Fair employment and reward structures. Where pay is
related to productivity and equal for both men and
women, and where hiring and firing practices are seen
to be fair, respondents report reduced concern over the
impacts of the virus on their business and their
communities.8
• Positive perceptions of an economy’s prospects over
the next year. Economic confidence reduces concern
about the impact on firms, but not about impact on
communities.
Other factors, those related to a government’s broader
policy and performance, are seen as important for
community resilience towards HIV, but not for firms (see
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Figure 6: National governance influences business confidence about the local
HIV response
figure 6). The effectiveness of the legislative body, trust in
politicians, increased public spending, equitable
healthcare provision and other social policies, an
education system that meets competitive needs, and a
government that focuses on poverty reduction are all
thought by firms to reduce the community impacts of
HIV/AIDS.
In sum, it appears that a broad-based effort to combat
HIV/AIDS would be viewed favourably by business.
HIV/AIDS is seen not just as a challenge for the health
sector, but one that raises more fundamental questions
about the “fitness” of a society and its ability to protect
itself from harm.
P a r t  2 :  T h e  B u s i n e s s  R e s p o n s e
16
• Globally, most firms (71%) do not have policies to tackle
HIV/AIDS.
• Only in countries with an HIV prevalence above 20% do
the majority of firms have policies. These policies tend
to be more comprehensive than those of firms in lower
prevalence settings.
• Except in the hardest hit countries, informal policies are
more common than written policies. Informal policies do
not cover as many prevention and treatment aspects as
formal policies.
• Firms that have conducted quantitative HIV/AIDS risk
assessments are much more likely to have policies. This
implies either that concerned firms obtain the facts and
act on them, or that studies spur previously
unconcerned firms to action. The data, however, do not
allow us to determine causality.
• Prevention, rather than more complex and costly
treatment and care programmes, is the main focus of
programmes.
• Confidence in policies is mixed, although firms in high-
prevalence settings are more confident than the
average, possibly because more of them have policies.
Respondents were asked to describe the state of their
company’s HIV/AIDS policy. Over two-thirds of firms have
no policy, and informal policies outnumber formal ones
(table 14). Not surprisingly, the more concerned firms are,
the more likely they are to have policies.
National HIV prevalence is a strong determinant of
whether a firm is likely to have a policy (see figure 7). In
countries with over 20% infection rates, 72% of firms
have some kind of policy, compared to 15% in countries
where prevalence is below 1%. These policies are more
likely to be formal than informal, as it appears that only
when an epidemic is rampant do many firms draw up
written plans to tackle the disease. Firms in low-income
countries, too, are more likely to have either a written or
informal HIV/AIDS policy than those in wealthier settings.
Formal risk assessments are important
Firms that have carried out quantitative HIV/AIDS risk
assessments are more likely to have policies to tackle the
virus. Globally, 16% of these firms have written policies
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Figure 7: Worsening epidemics drive formal development of HIV policies
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and 24% informal policies. We do not know whether the
study or the policy came first, so it is difficult to be certain
about causality. However, even in the event that studies
were carried out after policies were developed, the fact
that firms continued with their policies after conducting
studies suggests the results indicated a need to continue
acting. Of firms that have not carried out a study, 5%
have written policies and 11% informal policies.
In the high-prevalence regions where conducting a study
is more likely to show an impact on operations, however,
firms with studies are over twice as likely to have written
policies as those that have not assessed the threat.9
Although causality cannot be inferred, there is a
possibility, therefore, that at least some firms in such
settings, once they realize the impact of HIV/AIDS on their
operations, respond by drawing up a strategy to counter
it. Those firms that do not investigate impacts,
meanwhile, produce a more limited response.
Firms with written HIV policies (%)
Of firms with Of firms without
quantitative quantitative
assessments assessments
Overall 16 5
HIV prevalence > 20% 79 37
The survey also explores the elements of a firm’s
HIV/AIDS policy (we look here at the 19% of firms that
report having an informal or written HIV/AIDS policy):
• Prevention programmes focus on providing information
about the risks of infection. 49% of firms with HIV
policies offer this information, while 32% provide
voluntary HIV testing and 28% provide condoms.
• A small proportion of firms include these measures in
their programmes but report not implementing them
(13% for information provision, 12% for voluntary
testing and 8% for condom provision).
• Employees are the main target of prevention
programmes, with 39% of programmes targeting
workers, 16% workers’ families, 12% the surrounding
community, 9% high-risk community groups such as
sex workers, and 10% suppliers, contractors or
customers.
• The comprehensiveness of policies tends to increase
with the HIV prevalence of the country in which the firm
operates.
• Firms that have written HIV/AIDS policies are more likely
to incorporate each of the prevention and treatment
elements than firms with informal policies (see figure 8).
This suggests that formal policies are more rigorous
than informal policies.
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Figure 8: Formalizing policies increases the quality of programmes
Programmes tend to focus on prevention
Firms in high-prevalence countries are more likely to have
prevention programmes that incorporate information,
condom provision and voluntary testing. 82% of firms in
countries with over 20% prevalence provide information
about infection, 69% provide condoms and 57%
voluntary testing.
Programmes focus less on treatment than prevention.
34% of respondent firms with HIV policies provide
treatment for sexually transmitted infections (STIs) and
27% for opportunistic infections (OIs); 23% provide anti-
retroviral drugs (ARVs); and 16% provide home-based
care for ill-health retirees. The “no response” rate is
higher, around 23%, for treatment than for prevention
elements (around 12%), probably suggesting that some
HIV programmes include no treatment aspects.
Unsurprisingly, while prevention programmes are more
comprehensive in low-income countries, for some
aspects of treatment, this is reversed, even though high-
income country firms have many fewer AIDS cases to
treat. The costs of ARVs and home-based care appears
to have an impact on what treatment and care firms are
willing or able to offer:
• 30% of firms in high-income countries provide ARVs,
for example, compared to 17% of those in low-income
settings.
• 23% of high-income country firms provide home-based
care for those who have had to retire from work due to ill
health. In low-income countries, only 11% offer such care.
• For treatment of STIs and OIs, the gap is much
narrower, possibly because the latter are less expensive
and more likely to be included in insurance schemes
than are ARVs and home-based care.
As with prevention activities, however, treatment provision
increases as the epidemic worsens. In countries with the
highest prevalence rates, 58% of firms with policies
provide STI treatment, 50% OI treatment, 42% ARVs and
18% home-based care.
Few believe programmes will be sufficient
Respondents were then asked if their companies’ policies
were sufficient to manage the impact of HIV/AIDS in the
next five years (table 15). In general, firms with policies are
confident in their ability to manage the impact of HIV on
the business, although a significant minority remain
worried despite having enacted programmes:
• Globally, 41% of firms with policies or programmes are
strongly confident that they are sufficient to cope with
HIV/AIDS, while 13% strongly lack confidence.
• Firms in high-income countries are the most confident,
with 67% of those with policies strongly confident
compared to 24% in low-income countries.
• When looked at by national HIV prevalence, confidence
declines as prevalence rates rise but then increases
again above the 20% prevalence threshold (see figure
9). This apparent anomaly is driven by firms in South
Africa, where 61% of firms with policies are strongly
confident in them.
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Figure 9: Few firms have policies, but most of those that do are confident in them
Stigma reduces programme effectiveness
One obstacle to a policy’s effectiveness lies in the stigma
and discrimination surrounding HIV/AIDS. When asked
about these factors, 40% of firms with policies reported
that stigma has a negative effect on their implementation.
50% reported no effect. Stigma and discrimination cause
more problems in low-income countries, where 57% of
respondents report a negative effect (compared to 21% in
high-income settings). In high-prevalence countries, too,
taboos around AIDS can obstruct programmes – over
60% of firms with policies in countries with over 5%
infection rates report some negative impacts from stigma.
In low-prevalence environments, only 27% report impacts.
Firms’ own policies are rarely designed to combat stigma
and discrimination. Only 13% of firms prohibit disclosure
of workers’ HIV status, and only 11% prohibit
discrimination in promotion, pay, benefits or hiring based
on HIV status. Of firms that have HIV/AIDS policies,
around one in three has such prohibitions. These rules are
more common in countries with very high HIV prevalence.
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“The contribution of business in the fight
against AIDS goes far beyond the individual
workplace. Business can have a wider-
ranging impact as advocates for change,
by speaking up about the HIV/AIDS
epidemic and what can be done to stop it.
Silence and stigma drive the virus
underground and fuel its spread.”
Kofi Annan, Secretary-General of the United
Nations, 1 December 2004
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Figure 10: Concerns about and responses to HIV are not often commensurate 
This section assesses reactions and responses to
HIV/AIDS at a regional level (see figure 10).10
• Sub-Saharan African firms are the most concerned
about the current and future impacts of HIV/AIDS.
Caribbean firms are also worried, with firms elsewhere
much less concerned.
• Sub-Saharan African firms report greater impacts on
operating costs than firms elsewhere, especially on
productivity and absenteeism.
• North American and sub-Saharan African firms tend to
have the most comprehensive policies (see figure 11).
• Relative to their concern over the disease, however,
sub-Saharan African firms are the least likely to have
HIV/AIDS policies. Concern also significantly outweighs
action in Eastern Europe and Central Asia and the
Caribbean.
• With the exception of South and South-East Asia, firms
in wealthier regions are more likely to be confident in
their HIV/AIDS policies than those in poorer areas.
Firms in South and South-East Asia are more confident
than other developing regions, with African firms the
least confident in their response.
Sub-Saharan Africa
Sub-Saharan African firms are by far the most worried in
the world about the impact of HIV/AIDS (see figure 10).12
With the epidemic stabilizing in parts of the continent,
however, the difference between current concerns and
future fears is smaller than in regions such as the
Caribbean, East Asia and Latin America, where the
epidemic is less mature. African firms are also most
worried about malaria and TB, but AIDS is establishing
itself as the continent’s leading future health threat in the
eyes of respondents.
Only 14% of African firms have conducted quantitative
studies of infection rates among their employees – the
same proportion as in the survey as a whole. 69% do not
know workforce HIV prevalence rates. As in other regions,
respondents estimate lower prevalence rates in their firm
than would be expected from UNAIDS estimates, and
45% state that rates are higher in the community than in
their workforce.
Sub-Saharan African firms report greater impacts on
operations than firms elsewhere. 17% of African firms
report serious negative effects from death, disability and
funeral expenses, for example, compared to a survey
average of 5% (see figure 12). 38% report minimal
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Figure 1112: North American and sub-Saharan African firms tend to have the most
comprehensive policies 
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Figure 12: Sub-Saharan African businesses demonstrate the potential threats
facing other regions  
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impacts (survey average, 71%). The difference between
Africa and other areas is most pronounced with regard to
the impact of HIV/AIDS on productivity and absenteeism.
It may be that this aspect of operations is hit first and/or
hardest by HIV/AIDS.
15% of African firms have written HIV/AIDS policies and
19% informal policies, which is greater than the global
average. Of the African firms that have conducted
quantitative HIV/AIDS risk assessments, 37% have written
policies.
Programmes tend to focus on prevention, with 61%
providing information on infection risks and 52% providing
condoms. Care programmes are largely limited to
treatment of sexually transmitted infections (provided by
40% of firms with programmes) and opportunistic
infections (32%). Anti-retroviral drug provision (24%) and
home-based care (11%) are more limited. Firms are
generally less confident about their policies than
elsewhere. They are also more likely to report stigma, with
48% reporting some negative impacts of stigma on
HIV/AIDS programmes – double the survey average.
Sub-Saharan Africa is the only region that can be
compared directly to last year’s survey, due to differences
in methodology.13 As in other regions, firms appear to be
less worried about HIV/AIDS than they were a year ago,
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with only two of the 17 African countries surveyed in both
years (Botswana and Tanzania) reporting increased
concerns. This decline in concern comes despite a
perceived increase in estimates of workforce prevalence.
Part of the decline in concern over HIV/AIDS may be due
to an improved response to the disease. More African
firms have written policies than last year, while there is a
slight increase in provision of treatment and care. 
The Caribbean
Only in Africa are firms more concerned than those in the
Caribbean about the threat of HIV/AIDS. Over half of
Caribbean firms (55%) report some current impacts of the
virus on their business.14 21% report serious current
impacts. Both figures are much higher than the survey
average, and their concerns for the next five years, when
67% expect some impacts and 29% serious impacts, are
greater still. As in Africa and other areas, communities are
currently perceived as having higher prevalence rates than
workforces.
Impacts on company operations are also thought to be
low. Perceived effects on costs and productivity are lower
than the survey average, although revenues, which 20%
believe are seeing some negative effects, are more
seriously affected.
Relative to the prevalence rate in their countries (although
not relative to their level of concern), Caribbean firms are
responding more proactively than those in most regions
to the threat of HIV/AIDS. 29% of firms in the area have
some form of policy in place, compared to 19% of the
overall sample. Confidence in the policies, however, is
low. Only 33% of Caribbean firms with policies are
strongly confident in them – a lower proportion than
anywhere bar sub-Saharan Africa.
The content of HIV/AIDS policies in the Caribbean differs
somewhat from those elsewhere. Only 6% of Caribbean
policies, for example, provide condoms. They are also
more focused on combating stigma and discrimination
than policies in other regions. 20% of Caribbean firms
prohibit disclosure of HIV status – only North America has
more firms that do this. The effect of discrimination on
programme effectiveness is perceived as correspondingly
slightly lower than in most other developing regions.
East Asia
East Asian firms are conscious of an increasing, albeit
low-level, impact on their business from HIV/AIDS. 21%
of East Asian firms report some current impacts from
HIV/AIDS on their business, with 6% reporting serious
effects.15 Importantly, and in keeping with international
concerns about the expansion of the epidemic in Asia,
impacts are expected to grow in the next five years, with
31% expecting some negative effects in this period.
59% of East Asian firms do not know HIV prevalence
rates among their workers. Of those that provide an
estimate, nearly all (97%) believe rates are below 1%.
These estimates, which correspond with UNAIDS national
prevalence estimates for the region, are more likely than
those in other areas to be correct, as 31% of East Asian
firms have conducted quantitative risk assessment
studies (compared to 14% in the overall survey).
A high proportion of East Asian firms believe HIV
prevalence is higher in the external community than
among their staff. 71% are of this opinion (compared to
45% in the overall sample). The effect on East Asian
communities is not thought to be severe, however. 28%
of respondents report some current impacts (compared
to 38% in the overall survey).
East Asian firms are more concerned about the effect of
HIV/AIDS on other aspects of operations than on their
workforces. Around 25% report some current impacts on
costs, productivity and revenues, compared to an overall
sample average of around 20%. This may be because
East Asian economies rely heavily on imports and exports
and therefore have more dealings than most with harder
hit neighbouring regions – the data provide no further
clues, however.
The proportion of East Asian firms that have responded to
the disease with specific written policies is similar to that
in the overall sample, at 6%. Their content is tilted
towards prevention rather than treatment activities (not
surprisingly, given that the region is in the early stages of
the epidemic). Although 43% of respondents report
confidence in their policies, firms in other high-income
regions such as North America, Oceania and Western
Europe have much more faith in their programmes than
those in East Asia.
Eastern Europe and Central Asia
Firms in Eastern Europe and Central Asia are among the
least concerned about the current and future impacts of
HIV/AIDS on their business.16 19% of firms in the region
report some current impacts, compared to 30% in the
overall survey, with 29% expecting future impacts (37%
overall). HIV/AIDS is not yet having much impact on other
aspects of company operations either. Only around 10%
of respondents report negative effects on costs,
productivity and revenues, with only around 1 firm in 50
reporting serious impacts.
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Knowledge of workforce infection rates is lower in this
region than elsewhere. 73% of firms do not know
employee prevalence. Communities are thought to be
harder hit by the virus than businesses. 28% of firms
report some current impact on people in their locality.
The response to AIDS in Eastern Europe and Central Asia
reflects the relative lack of concern. Only 9% of firms have
an HIV/AIDS policy, with only 2% having specific written
programmes. Only in North Africa and the Middle East do
fewer firms have policies. Confidence in the response,
however, is similar to the average.
Latin America
Although currently less concerned than many other
regions, business leaders in Latin America perceive a
growing threat from HIV/AIDS.17 21% report some current
impact on their business (compared to 30% of the overall
sample). Impacts are expected to increase in the next five
years, however, with 35% expressing concern over the
near term.
Business operations have not been seriously affected by
AIDS. Over three-quarters of firms report minimal impacts
on costs, productivity and revenues. Few firms know
workforce prevalence rates, with 91% of those that do
provide an estimate believing they are below 1%.
The response of Latin American firms to the disease is
similar to the overall average. 75% have no policy, with
those that have responded to the threat mainly doing so
via informal means. The content of programmes is also
similar to the overall survey, with the exception that
condom provision is lower in Latin America (where 15% of
firms offer condoms, compared to 28% overall).
Interestingly, confidence in firms’ response to HIV/AIDS is
weaker than in most other regions. Only 48% of firms
with policies are confident they will be able to cope with
AIDS over the next five years. This may be at least in part
due to the perception that the threat of HIV/AIDS is
growing fast. Current policies may not be robust enough
to cope with what is felt to be an emerging epidemic.
North Africa and the Middle East
Only firms in Oceania and Western Europe are less
concerned than Middle Eastern and North African firms
about the current and future impacts of HIV/AIDS on their
business.18 81% of firms in the Middle East report no
current impacts, and 77% expect none in the next five
years. 99% of firms that estimate workforce infection rates
believe they are below 1%, and fewer than 3% have seen
any significant impacts on costs, productivity and revenue.
Firms in the region believe their local communities, too,
are largely unaffected by AIDS. Just 15% of firms report
negative effects on their localities – the lowest proportion
of any of the ten regions studied.
Not surprisingly, then, the response by firms to the virus is
very limited. Just 3% have a specific written policy for
tackling the disease, and 5% have informal policies. Few
firms prohibit discrimination against HIV-positive
individuals in promotion, pay and recruitment policies, and
only 5% prohibit disclosure of HIV status.
South and South-East Asia
After those in sub-Saharan Africa and the Caribbean,
firms in South and South-East Asia are the most
concerned about the current and future impacts of AIDS
on their business.19 37% of firms in the region report
some current impacts (compared to 30% in the survey
overall) and 41% expect future impacts (37% overall). 9%
expect future impacts to be serious.
Workforce HIV prevalence is thought to be similar in
South and South-East Asia to the overall sample. 90% of
those who estimate rates believe they are below 1%.
Despite this, about one in five respondents reports
current negative impacts on costs, productivity and
revenues.
Communities in South and South-East Asia, as in other
regions, are reported to be harder hit by AIDS than
businesses. 45% of firms in the region believe the disease
is having more impact outside of the companies than
inside, with 24% believing rates are the same.
The response by firms in the region has been more
extensive than the average response worldwide. 25% of
South and South-East Asian firms have some form of
policy for tackling AIDS, compared to an average of 19%
elsewhere. Confidence in those policies, too, is slightly
higher, with 39% confident that existing efforts will be
effective, compared to an average of 34% in the overall
sample. The content of policies is consistent with those
elsewhere.
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• Concern over HIV/AIDS varies little by industry, with
only the hotel and restaurant industry significantly more
concerned than the average.
• Responses, however, do vary. Certain sectors are more
actively protecting their workers’ health than others.
For the first time, it was possible to explore business
executives’ concerns about HIV/AIDS according to their
sector. 25% of firms in this year’s survey work in the
manufacturing sector; 10% in wholesale and retail trade;
10% in financial intermediation; 9% in transport, storage
and communications; 5% in construction; and 42% in
other sectors.20
Perceptions of impact do not vary from industry to
industry:
• After controlling for location, national income and HIV-
prevalence levels in their country, firms in different
industries perceive similar impacts from the virus. Firms
in potentially high-risk industries such as mining and
transport perceive no greater impacts than those in, for
example, education, retail or agriculture.
• The only exception to this is the hotel and restaurant
industry, which has a higher than average level of
concern over the current and future impacts of the
disease after accounting for controlling factors.
Firm size does have an impact, however. Larger firms
(with more than fifty employees) are more concerned than
smaller firms about the current and future effects of
HIV/AIDS on their business.
Responses, however, differ markedly from sector to
sector. Firms working in the health and social sectors are
the most likely to have written policies. Mining firms, too,
are more likely than most to have policies, which may
account for their confidence in their programmes to tackle
the disease’s impacts. Firms in the hotel and restaurant
sector, fishing, manufacturing and transport are also more
likely to have policies, although in the case of the hotel
sector, this does not reassure respondents. The industries
where policies are least prevalent include agriculture,
construction, real estate and retail.
These differences, which occur despite similar cross-
industry levels of concern, could be due to various
factors. It may be that those industries that respond more
fully to the virus are less worried as a consequence.
Certain sectors may also be generally more conscious of
their workers’ health. Or it may be that certain industries
are subject to more pressure from governments and
NGOs to develop HIV/AIDS policies, even though their
own assessment suggests they are no harder hit by the
disease than anyone else.
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Figure 13: Companies are less concerned about the HIV pandemic in 2004 than
in 2003 
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Figure 14:23
Business leaders less concerned about HIV/AIDS
this year than last
• Comparisons between the 2003-2004 and 2004-2005
surveys show declining levels of concern about
HIV/AIDS from all types of respondents, but rising levels
of action reported by those based in high-prevalence
countries. Increased action is unlikely to fully account
for declining concern, but it represents a very
encouraging sign.
Drawing comparisons between data from the 2003-2004
and 2004-2005 surveys provides a guide as to how
business leaders’ attitudes to HIV/AIDS are developing.21
Firms appear to be slightly less worried about HIV/AIDS
than they were a year ago (see figures 13 and 14).22
This finding applies across all income and HIV prevalence
groups. The decline in concern is particularly marked in
low-income countries, where the proportion observing
serious impacts has dropped from 53% to 42%. Even
firms in countries with very high HIV prevalence, while still
worried about the disease, appear to be less concerned
than they were a year ago. They are also more sanguine
about malaria and TB.
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Business leaders’ access to information and
perceptions vary
When asked what percentage of their employees they
estimated to be HIV-positive, business leaders are less
clear this year than last. The percentage of those who
either do not know or provide no response has risen from
36% to 66%. The proportion that conducted a
quantitative study, however, has remained more or less
constant, although the wording of the question changed
slightly.24 For the most part, business estimates of
prevalence are similar across the two surveys. In
countries with the worst epidemics, however, firms
estimate slightly higher workforce prevalence rates this
year than they did last year.
Last year’s survey found that 20% of firms considered
current and future impacts on their communities to be
serious, with 50% expecting some impact. This year, 12%
of firms report a current serious impact, with 38%
reporting some current effect. This decline is similar to
that reported for impact at firm level. It may be accounted
for, however, by the different question wording in the two
surveys.
There are few changes in perceptions of the impact of
HIV/AIDS on various aspects of a company’s operations.
Only the effect on revenues is reported to have increased,
and that only slightly, with 5% of firms reporting serious
impacts (compared to 4% last year) and 19% some
impacts (17% last year).
In any case, slightly more companies are
responding to the epidemic
We do not have sufficient information to determine why
levels of concern about the epidemic appear to be falling.
Among many other reasons, it could be due to changes
in the nature and spread of the epidemic, the prominence
of other challenges, or the adequacy of firm response.
Our analysis has established that the decline in concern is
not due to changes in the sample. This survey allows us
to examine the last of these possibilities.25
In 2003-2004, 6% of firms reported having written
policies. In 2004-2005, 7% have written policies. There is
little change too when looked at by income group. With
HIV-prevalence levels, however, large differences emerge
(figure 15). At low- and mid-prevalence rates (up to 19%
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Figure 15: Written policies increased by two-thirds in the last year – but only in
hardest hit countries 
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prevalence), the proportion of firms with written policies
has remained steady. This is counter-balanced, however,
by a large increase among firms in countries with high-
prevalence rates. In the countries that are hardest hit by
AIDS, there has been a significant increase in the
proportion of firms with policies since the 2003-2004
survey. Firms in these settings, it appears, have decided
that the time has come to act against the virus. In 2003-
2004, 27% had written HIV/AIDS policies. In 2004-2005,
47% of firms have produced formal responses to the
disease.
Confidence in policies and the content of programmes
follows a similar pattern. In high-prevalence countries,
where many more firms have policies, confidence has
risen markedly. Given that risks that are actively managed
are likely to cause less concern to firms than those that
have not been seriously addressed, this finding is not
surprising, particularly if increased business HIV/AIDS
efforts reflect intensifying national efforts to tackle the
virus.
The content of programmes follows a similar pattern.
Overall, there are few differences in content, while in high-
prevalence countries, firms have stepped up both their
prevention and treatment activities significantly (figure 16).
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Figure 16: Business activity against HIV/AIDS has increased significantly in the
last year 
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Get informed
In general, firms appear to be making decisions on
whether and how to respond to HIV/AIDS without much
information regarding its effects on their business. The
finding that firms that have conducted studies are more
likely to have policies applies across all prevalence groups
and all income groups. Not surprisingly, it is most evident
in the regions most affected by HIV/AIDS. Given that firms
that actively manage risks are likely to be better placed to
avoid their consequences, it is in the interest of
businesses to determine HIV’s likely impacts.
Firms that are based in or have dealings with hard hit
countries would derive particular benefit from assessing
the scale of the threat. In the majority of cases, however,
firms in hard hit countries that carry out studies feel
compelled either to develop a response to the disease or
to continue with existing HIV programmes. This should
provide a warning signal to firms that have so far failed to
examine the threat. It also suggests that there would be
benefits to developing a more sophisticated
understanding of the short- and long-term risks that
businesses face in low-prevalence environments, as well
as recommendations on cost-effective, scaled
interventions. Even in low-prevalence settings, companies
might benefit from policies underpinning other
programmatic elements to ensure sustained management
support and provide a basis to reduce stigma and fear of
discrimination.
Focusing on raising firms’ awareness of the impacts of
HIV/AIDS is likely to be a beneficial course of action for
advocates of business action on HIV/AIDS. Advocates
working in such settings would be well advised to find out
why some firms have not conducted studies or
implemented programmes. It may be that they lack the
knowledge or capacity to design them, highlighting the
importance of governments and NGOs to disseminate
good practice on study design or to develop cost-
effective templates for studies and programmes.
Combining persuasion with assistance may be an
attractive approach for both advocates and firms.
Build alliances
When firms do decide to act to combat HIV/AIDS, they
appear uncertain as to how to go about it. At present,
72% of firms’ prevention programmes do not provide
condoms (a cheap, effective prevention method) to their
workers. Over half do not provide information about HIV,
and informal policies outweigh more comprehensive,
formal approaches to tackling the disease. Even in the
hardest hit countries, a large proportion of firms have not
acted on their concerns over the virus, and many of those
that have acted perceive their responses to be inadequate.
As we have seen, firms seem to favour a broad response
to HIV/AIDS. Where they lack and are unable to access
sufficient knowledge, therefore, it is in governments’ and
other advocates’ interests to provide it. Firms that see
government as a trustworthy partner feel more confident
about fending off HIV/AIDS. Governments and NGOs that
have access to international networks with knowledge of
how to combat the disease and can also gather and
disseminate information from other firms within their
countries are well placed to help companies respond
more effectively. National business coalitions against HIV
as well as other business associations (industry
organizations, chambers of commerce, etc.) should
emphasize information provision and good practice
dissemination in their work with firms on HIV/AIDS,
perhaps focusing on creating templates or computerized
models to simplify the policy development process.
It may also be in governments’ – and indeed international
donors’ – interest to help out with the costs of
interventions. The cost of treatment seems to prevent
many firms in hard-hit settings from incorporating anti-
retroviral drug provision into their programmes, but as the
epidemic matures, treatment will become ever more vital.
Clearly some firms can afford treatment but decide not to
implement it. Governments wanting to enlist these firms’
help in treatment campaigns will need to seek out suitable
incentives to persuade them to invest. Some companies,
however, lack the financial resources. Governments may
benefit from seeking out willing but cash-strapped firms
and devising partnership arrangements with them,
perhaps in conjunction with other firms in similar
situations.
Plan ahead
There are many unanswered questions about how
businesses should respond to HIV/AIDS. We do not
know, for example, whether quantitative risk assessments
persuade firms to act or whether firms that carry out
assessments would have acted anyway. Do some firms
carry out studies and decide not to act? If so, what is
their rationale and how far into the future are they looking
when measuring the likely impacts? The effects of
HIV/AIDS on an individual worker are likely to be felt
several years after he or she contracts the virus. Firms
looking only five years down the line, for example, may
perceive the likely impacts to be minimal, particularly if
employee turnover is such that an individual infected
today is unlikely to be working for the company when
AIDS kicks in. Is a long-term risk assessment, therefore, a
crucial step towards action? How, moreover, can such
assessments be modified to be more relevant to smaller
firms, whose smaller workforces make robust quantitative
analysis difficult?
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When a firm does decide to act, how can it demonstrate
the impact of its programmes? At present, many firms
lack confidence in their response – how can they
effectively monitor its impacts, and who should be
responsible for doing so? Reducing workforce stigma
around AIDS, for example, is an important goal but a
tough one to measure. Tracking progress on this may
provide a more immediate indicator as to whether a
programme is having an effect than measuring infection
rates, so effective monitoring systems are vital for the
long-term management of programmes.
Alliances, too, are a complex issue. How can firms build
effective alliances with governments and NGOs,
particularly in circumstances where such relationships
have traditionally been antagonistic rather than
cooperative? How can roles be defined to avoid overlap
and waste, and what indicators are needed to judge the
success of the alliance?
Firms are in a good position to reach large numbers of
individuals with both prevention and treatment measures.
Many governments are finding they lack the human
resources to deliver HIV/AIDS programmes exclusively
through the health system. Businesses may prove an
effective conduit for such programmes, and government-
business partnerships may strengthen the efforts of both
parties in the fight against HIV/AIDS.
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Appendix 1: The Survey
GCR – The Survey26
The 2003-2004 Executive Opinion Survey (of nearly 8,000
executives in 103 countries) found that business leaders
were somewhat concerned about the threat of HIV/AIDS
and its potential impact on their business.27 They believed
that their businesses would not be immune when
countries were hit hard by the virus, but felt that operating
costs would not be greatly affected. Respondents in poor
countries that were already experiencing high HIV
prevalence were most concerned, particularly if the
operated in countries that were seen as badly governed.
On the whole, businesses leaders lacked knowledge of
the risks they faced from AIDS. Even those most
concerned by the epidemic were not particularly active in
responding to the threat they faced and many business
leaders were unsatisfied by their own firm’s response to
the disease.
The 2004-2005 survey polled the views of 8,719 business
executives in 104 countries during the first five months of
2004. The lead person for each business in a given country
was asked to fill out the questionnaire via the Internet or
mail. The full survey takes about 30-40 minutes to
complete.28 The survey questions executives from firms of a
variety of sizes. However, smaller firms and those with lower
turnover are generally under-represented in the survey.
Nine questions address HIV/AIDS, covering three areas:
• The current and future impact of malaria, tuberculosis
and HIV/AIDS on a respondent’s company.
• The current impact of these diseases on the community
in which the company operates.
• The nature and extent of companies’ response to
HIV/AIDS.
A full account of how we have reported the data is
provided in Appendix 2. 
Appendix 2: Reporting the Data
Many of the questions on HIV/AIDS include seven-point
Likert scales. The World Economic Forum practice is for
numbers 1 to 3 on the scale to signify agreement with the
left-hand proposition, 5 to 7 to equal agreement with the
right-hand proposition, and 4 to be neutral. There are two
types of seven-point scales employed in the HIV/AIDS
section of the questionnaire:
• Type 1 (used by most questions) requires a respondent
to score impact against a 1-7 scale, where 1 means
extremely serious impact and 7 means not a problem,
or no impact at all. Logically, any answer other than 7
implies at least some impact – although this contradicts
World Economic Forum instructions to treat 4 as
neutral. The data are therefore difficult to interpret, but
we have decided the best way is to set three standards
– 1-2 as a serious impact, 1-5 for some impact and 6-7
for minimal impact. This does not provide numbers that
sum neatly to 100%, but appears to be the best
possible interpretation in other regards.
• Type 2 (used in only one question), which uses a 7-
point Likert scale and where 1-3 clearly indicates the
negative, 4 neutrality, and 5-7 the positive. We have
also reported 1-2 (strongly negative) and 6-7 (strongly
positive).
We break down data by national HIV prevalence, national
income group and region, as well as make comparisons
between responses in 2003 and 2004.
The table on the right shows how each question is
reported.
Appendix 3: The Global
Competitiveness Report
The Global Competitiveness Report (GCR), first published
in 1979, monitors the competitiveness of the world’s
economies. It asks why some countries enjoy sustained
growth, while others fail to grow or see erosions in their
living standards.29 The 2004-2005 GCR was published on
14 October 2004.30 Its headline findings were that Finland
is the most competitive economy in the world, followed
by the United States, Sweden, Taiwan, Denmark and
Norway. In sub-Saharan Africa, the region most affected
by HIV/AIDS, most economies fall into the lower half of
the rankings (with South Africa ranked highest, at 41st of
104 countries).
The Executive Opinion Survey is at the heart of the GCR’s
Growth Competitiveness and Microeconomic
Competitiveness Indexes. It asks business leaders a
series of questions about the country in which they
operate, covering issues such as tax, regulation,
infrastructure, corruption and the macroeconomic
environment.
In recent years, the survey has increased its focus on
social and environmental issues, and their impacts on
economic and business competitiveness. In 2003-2004, it
included, for the first time, a series of questions that
explored the impact of HIV/AIDS on the business
environment. The response rate in 2004-2005 was 8%.
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A p p e n d i x  2 :  Ta b l e
Question Topic Left-hand scale Right-hand scale Method for reporting data
q7.20a-c Current impact of Malaria, Extremely serious Not a problem 1-2 A serious impact
TB and HIV/AIDS 1-5 Some impact
on company 6-7 Minimal impact
q7.21a-c Impact of Malaria, Extremely serious Not a problem 1-2 A serious impact
TB and HIV/AIDS 1-5 Some impact
on company 6-7 Minimal impact
in next 5 years
q7.22 Impact of HIV/AIDS Extremely serious Not a problem 1-2 A serious impact
on community 1-5 Some impact
6-7 Minimal impact
q7.23a Estimate of workforce Tick prevalence category Report proportion in each category 
prevalence or don’t know and proportion of don’t knows/no responses
q7.23b Estimate based on study – Yes Report proportion of yes, proportion of no,
– No and proportion of don’t know/no response
q7.23c Prevalence of HIV in – Prevalence higher in Report proportion of prevalence higher in
workforce relative workforce than country workforce than country.
to country – Prevalences are the same Report proportion that believes prevalence 
– Prevalence higher in is the same.
country than workforce Report proportion of prevalence higher
in country than workforce.
Report proportion of don’t knows/no 
responses.
q7.24 State of HIV/AIDS policy – No policy Report proportion of No Policy.
– Informal company policy Report proportion with informal company 
– Specific HIV/AIDS policy.
written policy Report proportion with specific HIV/AIDS 
written policy
q7.25 HIV/AIDS policy sufficient Current policies and Current policies and 1-3 Not confident in effectiveness
to manage impact programmes will not be programmes will not be 4 Neutral - neither confident nor not 
over next 5 years sufficient and/or effective sufficient and/or effective confident
5-7 Confident in effectiveness
1-2 Strongly lacking in confidence
6-7 Strongly confident
q7.26a-e Current impact on various Significant negative impact Not relevant 1-2 A serious impact
aspects of business 1-5 Some impact
6-7 Minimal impact
q7.27 Features of HIV/AIDS – No Proportion in each category.
policy and programme – Yes but not implemented Report for all respondents
– Yes Report for respondents with formal policy 
(q7.24 as filter)
q7.28 Effect of HIV/AIDS Significant negative impact Not a problem 1-2 A serious impact
stigma on policy and/or 1-5 Some impact
programme 6-7 Minimal impact
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Table 1: Firms surveyed compared to population by region
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Table 2: Firms surveyed compared to population by country’s income group
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Table 3: Firms surveyed compared to population by country’s UNAIDS HIV
prevalence estimates
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Table 4: How serious do you consider the current impact of malaria on your
company?
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Table 5: How serious do you consider the current impact of tuberculosis on
your company?
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Table 6: How serious do you consider the current impact of HIV/AIDS on your
company?
&RXQWU\
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VHULRXV
LPSDFW
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Table 7: How serious do you consider the future impact of malaria on your
company in the next five years?
&RXQWU\
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Table 8: How serious do you consider the future impact of tuberculosis on your
company in the next five years?
&RXQWU\
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&RORPELD    
&RVWD5LFD    
&URDWLD    
&\SUXV    
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Table 9: How serious do you consider the future impact of HIV/AIDS on your
company in the next five years?
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Table 10: How serious do you consider the current impact of HIV/AIDS in the
local communities in which your company operates?
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6SDLQ       
6UL/DQND       
6ZHGHQ       
6ZLW]HUODQG       
7DLZDQ       
7DQ]DQLD       
7KDLODQG       
7ULQLGDG	7REDJR       
7XQLVLD       
7XUNH\       
8JDQGD       
8NUDLQH       
8QLWHG$UDE(PLUDWHV       
8QLWHG.LQJGRP       
8QLWHG6WDWHV       
8UXJXD\       
9HQH]XHOD       
9LHWQDP       
=DPELD       
=LPEDEZH       
,QFRPHJURXSVXEWRWDO
/RZLQFRPH       
/RZHUPLGGOHLQFRPH       
8SSHUPLGGOHLQFRPH       
+LJKLQFRPH       
81$,'6+,9SUHYDOHQFHVXEWRWDO
3UHYDOHQFH       
3UHYDOHQFH       
3UHYDOHQFH       
3UHYDOHQFH       
3UHYDOHQFH       
3UHYDOHQFH!       
3UHYDOXQFODVVLILHG       
5HJLRQDOVXEWRWDO
&DULEEHDQ       
(DVW$VLD       
(DVW(XURSH	
&HQWUDO$VLD
      
/DWLQ$PHULFD       
1RUWK$IULFD	
0LGGOH(DVW
      
2FHDQLD       
1RUWK$PHULFD       
6RXWK	
6RXWK(DVW$VLD
      
6XE6DKDUDQ$IULFD       
:HVWHUQ(XURSH       
2YHUDOO       
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Table 11: What percentage of your employees would you estimate to be HIV
positive?
&RXQWU\
%DVHGRQD
VWXG\
1RWEDVHG
RQDVWXG\
1R
UHVSRQVH
$OJHULD   
$QJROD   
$UJHQWLQD   
$XVWUDOLD   
$XVWULD   
%DKUDLQ   
%DQJODGHVK   
%HOJLXP   
%ROLYLD   
%RVQLDDQG+HU]HJRYLQD   
%RWVZDQD   
%UD]LO   
%XOJDULD   
&DQDGD   
&KDG   
&KLOH   
&KLQD   
&RORPELD   
&RVWD5LFD   
&URDWLD   
&\SUXV   
&]HFK5HSXEOLF   
'HQPDUN   
'RPLQLFDQ5HSXEOLF   
(FXDGRU   
(J\SW   
(O6DOYDGRU   
(VWRQLD   
(WKLRSLD   
)LQODQG   
)UDQFH   
*DPELD   
*HRUJLD   
*HUPDQ\   
*KDQD   
*UHHFH   
*XDWHPDOD   
+RQGXUDV   
+RQJ.RQJ   
+XQJDU\   
,FHODQG   
,QGLD   
,QGRQHVLD   
,UHODQG   
,VUDHO   
,WDO\   
-DPDLFD   
-DSDQ   
-RUGDQ   
.HQ\D   
.RUHD   
/DWYLD   
/LWKXDQLD   
/X[HPERXUJ   
0DFHGRQLD)<5   
0DGDJDVFDU   
0DODZL   
0DOD\VLD   
0DOL   
0DOWD   
0DXULWLXV   
0H[LFR   
0RURFFR   
0R]DPELTXH   
1DPLELD   
1HWKHUODQGV   
1HZ=HDODQG   
1LFDUDJXD   
1LJHULD   
1RUZD\   
3DNLVWDQ   
3DQDPD   
3DUDJXD\   
3HUX   
3KLOLSSLQHV   
3RODQG   
&RXQWU\
%DVHGRQD
VWXG\
1RWEDVHG
RQDVWXG\
1R
UHVSRQVH
3RUWXJDO   
5RPDQLD   
5XVVLDQ)HGHUDWLRQ   
6HUELD	0RQWHQHJUR   
6LQJDSRUH   
6ORYDN5HSXEOLF   
6ORYHQLD   
6RXWK$IULFD   
6SDLQ   
6UL/DQND   
6ZHGHQ   
6ZLW]HUODQG   
7DLZDQ   
7DQ]DQLD   
7KDLODQG   
7ULQLGDG	7REDJR   
7XQLVLD   
7XUNH\   
8JDQGD   
8NUDLQH   
8QLWHG$UDE(PLUDWHV   
8QLWHG.LQJGRP   
8QLWHG6WDWHV   
8UXJXD\   
9HQH]XHOD   
9LHWQDP   
=DPELD   
=LPEDEZH   
,QFRPHJURXSVXEWRWDO
/RZLQFRPH   
/RZHUPLGGOHLQFRPH   
8SSHUPLGGOHLQFRPH   
+LJKLQFRPH   
81$,'6+,9SUHYDOHQFHJURXSVXEWRWDO
3UHYDOHQFH   
3UHYDOHQFH   
3UHYDOHQFH   
3UHYDOHQFH   
3UHYDOHQFH   
3UHYDOHQFH!   
3UHYDOHQFHXQFODVVLILHG   
5HJLRQDOVXEWRWDO
&DULEEHDQ   
(DVW$VLD   
(DVWHUQ(XURSH	&HQWUDO$VLD   
/DWLQ$PHULFD   
1RUWK$IULFD	0LGGOH(DVW   
2FHDQLD   
1RUWK$PHULFD   
6RXWK	6RXWK(DVW$VLD   
6XE6DKDUDQ$IULFD   
:HVWHUQ(XURSH   
2YHUDOO   
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Table 12: Is your prevalence estimate based on the result of a quantitative
HIV/AIDS risk assessment (e.g., company based testing, actuarial calculation)?
&RXQWU\
+LJKHULQ
ZRUNIRUFH
WKDQ
FRXQWU\
3UHYDOHQ
FHVDUH
WKHVDPH
+LJKHULQ
FRXQWU\
WKDQ
ZRUNIRUFH
1R
UHVSRQVH
$OJHULD    
$QJROD    
$UJHQWLQD    
$XVWUDOLD    
$XVWULD    
%DKUDLQ    
%DQJODGHVK    
%HOJLXP    
%ROLYLD    
%RVQLDDQG+HU]HJRYLQD    
%RWVZDQD    
%UD]LO    
%XOJDULD    
&DQDGD    
&KDG    
&KLOH    
&KLQD    
&RORPELD    
&RVWD5LFD    
&URDWLD    
&\SUXV    
&]HFK5HSXEOLF    
'HQPDUN    
'RPLQLFDQ5HSXEOLF    
(FXDGRU    
(J\SW    
(O6DOYDGRU    
(VWRQLD    
(WKLRSLD    
)LQODQG    
)UDQFH    
*DPELD    
*HRUJLD    
*HUPDQ\    
*KDQD    
*UHHFH    
*XDWHPDOD    
+RQGXUDV    
+RQJ.RQJ    
+XQJDU\    
,FHODQG    
,QGLD    
,QGRQHVLD    
,UHODQG    
,VUDHO    
,WDO\    
-DPDLFD    
-DSDQ    
-RUGDQ    
.HQ\D    
.RUHD    
/DWYLD    
/LWKXDQLD    
/X[HPERXUJ    
0DFHGRQLD)<5    
0DGDJDVFDU    
0DODZL    
0DOD\VLD    
0DOL    
0DOWD    
0DXULWLXV    
0H[LFR    
0RURFFR    
0R]DPELTXH    
1DPLELD    
1HWKHUODQGV    
1HZ=HDODQG    
1LFDUDJXD    
1LJHULD    
1RUZD\    
3DNLVWDQ    
3DQDPD    
3DUDJXD\    
3HUX    
3KLOLSSLQHV    
3RODQG    
&RXQWU\
+LJKHULQ
ZRUNIRUFH
WKDQ
FRXQWU\
3UHYDOHQ
FHVDUH
WKHVDPH
+LJKHULQ
FRXQWU\
WKDQ
ZRUNIRUFH
1R
UHVSRQVH
3RUWXJDO    
5RPDQLD    
5XVVLDQ)HGHUDWLRQ    
6HUELD	0RQWHQHJUR    
6LQJDSRUH    
6ORYDN5HSXEOLF    
6ORYHQLD    
6RXWK$IULFD    
6SDLQ    
6UL/DQND    
6ZHGHQ    
6ZLW]HUODQG    
7DLZDQ    
7DQ]DQLD    
7KDLODQG    
7ULQLGDG	7REDJR    
7XQLVLD    
7XUNH\    
8JDQGD    
8NUDLQH    
8QLWHG$UDE(PLUDWHV    
8QLWHG.LQJGRP    
8QLWHG6WDWHV    
8UXJXD\    
9HQH]XHOD    
9LHWQDP    
=DPELD    
=LPEDEZH    
,QFRPHJURXSVXEWRWDO
/RZLQFRPH    
/RZHUPLGGOHLQFRPH    
8SSHUPLGGOHLQFRPH    
+LJKLQFRPH    
81$,'6+,9SUHYDOHQFHJURXSVXEWRWDO
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH!    
3UHYDOHQFHXQFODVVLILHG    
5HJLRQDOVXEWRWDO
&DULEEHDQ    
(DVW$VLD    
(DVWHUQ(XURSH	&HQWUDO$VLD    
/DWLQ$PHULFD    
1RUWK$IULFD	0LGGOH(DVW    
2FHDQLD    
1RUWK$PHULFD    
6RXWK	6RXWK(DVW$VLD    
6XE6DKDUDQ$IULFD    
:HVWHUQ(XURSH    
2YHUDOO    
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Table 13: How would you describe the average prevalence of HIV in your
workforce relative to the rest of the country?
&RXQWU\ 1RSROLF\
,QIRUPDO
FRPSDQ\
SROLF\
:ULWWHQ
+,9$,'6
VSHFLILF
SROLF\
1R
UHVSRQVH
$OJHULD    
$QJROD    
$UJHQWLQD    
$XVWUDOLD    
$XVWULD    
%DKUDLQ    
%DQJODGHVK    
%HOJLXP    
%ROLYLD    
%RVQLDDQG+HU]HJRYLQD    
%RWVZDQD    
%UD]LO    
%XOJDULD    
&DQDGD    
&KDG    
&KLOH    
&KLQD    
&RORPELD    
&RVWD5LFD    
&URDWLD    
&\SUXV    
&]HFK5HSXEOLF    
'HQPDUN    
'RPLQLFDQ5HSXEOLF    
(FXDGRU    
(J\SW    
(O6DOYDGRU    
(VWRQLD    
(WKLRSLD    
)LQODQG    
)UDQFH    
*DPELD    
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Table 14: What is the state of your company’s HIV/AIDS policy?
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Table 15: Do you believe that your company’s current policies and programmes
are sufficient to effectively manage the impact of HIV/AIDS on your business in
the next five years? (Only responses of companies at least having informal
policies)
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3RUWXJDO    
5RPDQLD    
5XVVLDQ)HGHUDWLRQ    
6HUELD	0RQWHQHJUR    
6LQJDSRUH    
6ORYDN5HSXEOLF    
6ORYHQLD    
6RXWK$IULFD    
6SDLQ    
6UL/DQND    
6ZHGHQ    
6ZLW]HUODQG    
7DLZDQ    
7DQ]DQLD    
7KDLODQG    
7ULQLGDG	7REDJR    
7XQLVLD    
7XUNH\    
8JDQGD    
8NUDLQH    
8QLWHG$UDE(PLUDWHV    
8QLWHG.LQJGRP    
8QLWHG6WDWHV    
8UXJXD\    
9HQH]XHOD    
9LHWQDP    
=DPELD    
=LPEDEZH    
,QFRPHJURXSVXEWRWDO
/RZLQFRPH    
/RZHUPLGGOHLQFRPH    
8SSHUPLGGOHLQFRPH    
+LJKLQFRPH    
81$,'6+,9SUHYDOHQFHJURXSVXEWRWDO
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH!    
3UHYDOHQFHXQFODVVLILHG    
5HJLRQDOVXEWRWDO
&DULEEHDQ    
(DVW$VLD    
(DVWHUQ(XURSH	&HQWUDO$VLD    
/DWLQ$PHULFD    
1RUWK$IULFD	0LGGOH(DVW    
2FHDQLD    
1RUWK$PHULFD    
6RXWK	6RXWK(DVW$VLD    
6XE6DKDUDQ$IULFD    
:HVWHUQ(XURSH    
2YHUDOO    
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Table 16: How severely is HIV/AIDS currently affecting your death, disability and
funeral expenses?
&RXQWU\
6HULRXV
LPSDFW
6RPH
LPSDFW
0LQLPDO
LPSDFW
1R
UHVSRQVH
$OJHULD    
$QJROD    
$UJHQWLQD    
$XVWUDOLD    
$XVWULD    
%DKUDLQ    
%DQJODGHVK    
%HOJLXP    
%ROLYLD    
%RVQLDDQG+HU]HJRYLQD    
%RWVZDQD    
%UD]LO    
%XOJDULD    
&DQDGD    
&KDG    
&KLOH    
&KLQD    
&RORPELD    
&RVWD5LFD    
&URDWLD    
&\SUXV    
&]HFK5HSXEOLF    
'HQPDUN    
'RPLQLFDQ5HSXEOLF    
(FXDGRU    
(J\SW    
(O6DOYDGRU    
(VWRQLD    
(WKLRSLD    
)LQODQG    
)UDQFH    
*DPELD    
*HRUJLD    
*HUPDQ\    
*KDQD    
*UHHFH    
*XDWHPDOD    
+RQGXUDV    
+RQJ.RQJ    
+XQJDU\    
,FHODQG    
,QGLD    
,QGRQHVLD    
,UHODQG    
,VUDHO    
,WDO\    
-DPDLFD    
-DSDQ    
-RUGDQ    
.HQ\D    
.RUHD    
/DWYLD    
/LWKXDQLD    
/X[HPERXUJ    
0DFHGRQLD)<5    
0DGDJDVFDU    
0DODZL    
0DOD\VLD    
0DOL    
0DOWD    
0DXULWLXV    
0H[LFR    
0RURFFR    
0R]DPELTXH    
1DPLELD    
1HWKHUODQGV    
1HZ=HDODQG    
1LFDUDJXD    
1LJHULD    
1RUZD\    
3DNLVWDQ    
3DQDPD    
3DUDJXD\    
3HUX    
3KLOLSSLQHV    
3RODQG    
&RXQWU\
6HULRXV
LPSDFW
6RPH
LPSDFW
0LQLPDO
LPSDFW
1R
UHVSRQVH
3RUWXJDO    
5RPDQLD    
5XVVLDQ)HGHUDWLRQ    
6HUELD	0RQWHQHJUR    
6LQJDSRUH    
6ORYDN5HSXEOLF    
6ORYHQLD    
6RXWK$IULFD    
6SDLQ    
6UL/DQND    
6ZHGHQ    
6ZLW]HUODQG    
7DLZDQ    
7DQ]DQLD    
7KDLODQG    
7ULQLGDG	7REDJR    
7XQLVLD    
7XUNH\    
8JDQGD    
8NUDLQH    
8QLWHG$UDE(PLUDWHV    
8QLWHG.LQJGRP    
8QLWHG6WDWHV    
8UXJXD\    
9HQH]XHOD    
9LHWQDP    
=DPELD    
=LPEDEZH    
,QFRPHJURXSVXEWRWDO
/RZLQFRPH    
/RZHUPLGGOHLQFRPH    
8SSHUPLGGOHLQFRPH    
+LJKLQFRPH    
81$,'6+,9SUHYDOHQFHJURXSVXEWRWDO
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH!    
3UHYDOHQFHXQFODVVLILHG    
5HJLRQDOVXEWRWDO
&DULEEHDQ    
(DVW$VLD    
(DVWHUQ(XURSH	&HQWUDO$VLD    
/DWLQ$PHULFD    
1RUWK$IULFD	0LGGOH(DVW    
2FHDQLD    
1RUWK$PHULFD    
6RXWK	6RXWK(DVW$VLD    
6XE6DKDUDQ$IULFD    
:HVWHUQ(XURSH    
2YHUDOO    
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Table 17: How severely is HIV/AIDS currently affecting your medical expenses?
&RXQWU\
6HULRXV
LPSDFW
6RPH
LPSDFW
0LQLPDO
LPSDFW
1R
UHVSRQVH
$OJHULD    
$QJROD    
$UJHQWLQD    
$XVWUDOLD    
$XVWULD    
%DKUDLQ    
%DQJODGHVK    
%HOJLXP    
%ROLYLD    
%RVQLDDQG+HU]HJRYLQD    
%RWVZDQD    
%UD]LO    
%XOJDULD    
&DQDGD    
&KDG    
&KLOH    
&KLQD    
&RORPELD    
&RVWD5LFD    
&URDWLD    
&\SUXV    
&]HFK5HSXEOLF    
'HQPDUN    
'RPLQLFDQ5HSXEOLF    
(FXDGRU    
(J\SW    
(O6DOYDGRU    
(VWRQLD    
(WKLRSLD    
)LQODQG    
)UDQFH    
*DPELD    
*HRUJLD    
*HUPDQ\    
*KDQD    
*UHHFH    
*XDWHPDOD    
+RQGXUDV    
+RQJ.RQJ    
+XQJDU\    
,FHODQG    
,QGLD    
,QGRQHVLD    
,UHODQG    
,VUDHO    
,WDO\    
-DPDLFD    
-DSDQ    
-RUGDQ    
.HQ\D    
.RUHD    
/DWYLD    
/LWKXDQLD    
/X[HPERXUJ    
0DFHGRQLD)<5    
0DGDJDVFDU    
0DODZL    
0DOD\VLD    
0DOL    
0DOWD    
0DXULWLXV    
0H[LFR    
0RURFFR    
0R]DPELTXH    
1DPLELD    
1HWKHUODQGV    
1HZ=HDODQG    
1LFDUDJXD    
1LJHULD    
1RUZD\    
3DNLVWDQ    
3DQDPD    
3DUDJXD\    
3HUX    
3KLOLSSLQHV    
3RODQG    
&RXQWU\
6HULRXV
LPSDFW
6RPH
LPSDFW
0LQLPDO
LPSDFW
1R
UHVSRQVH
3RUWXJDO    
5RPDQLD    
5XVVLDQ)HGHUDWLRQ    
6HUELD	0RQWHQHJUR    
6LQJDSRUH    
6ORYDN5HSXEOLF    
6ORYHQLD    
6RXWK$IULFD    
6SDLQ    
6UL/DQND    
6ZHGHQ    
6ZLW]HUODQG    
7DLZDQ    
7DQ]DQLD    
7KDLODQG    
7ULQLGDG	7REDJR    
7XQLVLD    
7XUNH\    
8JDQGD    
8NUDLQH    
8QLWHG$UDE(PLUDWHV    
8QLWHG.LQJGRP    
8QLWHG6WDWHV    
8UXJXD\    
9HQH]XHOD    
9LHWQDP    
=DPELD    
=LPEDEZH    
,QFRPHJURXSVXEWRWDO
/RZLQFRPH    
/RZHUPLGGOHLQFRPH    
8SSHUPLGGOHLQFRPH    
+LJKLQFRPH    
81$,'6+,9SUHYDOHQFHJURXSVXEWRWDO
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH!    
3UHYDOHQFHXQFODVVLILHG    
5HJLRQDOVXEWRWDO
&DULEEHDQ    
(DVW$VLD    
(DVWHUQ(XURSH	&HQWUDO$VLD    
/DWLQ$PHULFD    
1RUWK$IULFD	0LGGOH(DVW    
2FHDQLD    
1RUWK$PHULFD    
6RXWK	6RXWK(DVW$VLD    
6XE6DKDUDQ$IULFD    
:HVWHUQ(XURSH    
2YHUDOO    
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Table 18: How severely is HIV/AIDS currently affecting your productivity and
absenteeism?
&RXQWU\
6HULRXV
LPSDFW
6RPH
LPSDFW
0LQLPDO
LPSDFW
1R
UHVSRQVH
$OJHULD    
$QJROD    
$UJHQWLQD    
$XVWUDOLD    
$XVWULD    
%DKUDLQ    
%DQJODGHVK    
%HOJLXP    
%ROLYLD    
%RVQLDDQG+HU]HJRYLQD    
%RWVZDQD    
%UD]LO    
%XOJDULD    
&DQDGD    
&KDG    
&KLOH    
&KLQD    
&RORPELD    
&RVWD5LFD    
&URDWLD    
&\SUXV    
&]HFK5HSXEOLF    
'HQPDUN    
'RPLQLFDQ5HSXEOLF    
(FXDGRU    
(J\SW    
(O6DOYDGRU    
(VWRQLD    
(WKLRSLD    
)LQODQG    
)UDQFH    
*DPELD    
*HRUJLD    
*HUPDQ\    
*KDQD    
*UHHFH    
*XDWHPDOD    
+RQGXUDV    
+RQJ.RQJ    
+XQJDU\    
,FHODQG    
,QGLD    
,QGRQHVLD    
,UHODQG    
,VUDHO    
,WDO\    
-DPDLFD    
-DSDQ    
-RUGDQ    
.HQ\D    
.RUHD    
/DWYLD    
/LWKXDQLD    
/X[HPERXUJ    
0DFHGRQLD)<5    
0DGDJDVFDU    
0DODZL    
0DOD\VLD    
0DOL    
0DOWD    
0DXULWLXV    
0H[LFR    
0RURFFR    
0R]DPELTXH    
1DPLELD    
1HWKHUODQGV    
1HZ=HDODQG    
1LFDUDJXD    
1LJHULD    
1RUZD\    
3DNLVWDQ    
3DQDPD    
3DUDJXD\    
3HUX    
3KLOLSSLQHV    
3RODQG    
&RXQWU\
6HULRXV
LPSDFW
6RPH
LPSDFW
0LQLPDO
LPSDFW
1R
UHVSRQVH
3RUWXJDO    
5RPDQLD    
5XVVLDQ)HGHUDWLRQ    
6HUELD	0RQWHQHJUR    
6LQJDSRUH    
6ORYDN5HSXEOLF    
6ORYHQLD    
6RXWK$IULFD    
6SDLQ    
6UL/DQND    
6ZHGHQ    
6ZLW]HUODQG    
7DLZDQ    
7DQ]DQLD    
7KDLODQG    
7ULQLGDG	7REDJR    
7XQLVLD    
7XUNH\    
8JDQGD    
8NUDLQH    
8QLWHG$UDE(PLUDWHV    
8QLWHG.LQJGRP    
8QLWHG6WDWHV    
8UXJXD\    
9HQH]XHOD    
9LHWQDP    
=DPELD    
=LPEDEZH    
,QFRPHJURXSVXEWRWDO
/RZLQFRPH    
/RZHUPLGGOHLQFRPH    
8SSHUPLGGOHLQFRPH    
+LJKLQFRPH    
81$,'6+,9SUHYDOHQFHJURXSVXEWRWDO
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH!    
3UHYDOHQFHXQFODVVLILHG    
5HJLRQDOVXEWRWDO
&DULEEHDQ    
(DVW$VLD    
(DVWHUQ(XURSH	&HQWUDO$VLD    
/DWLQ$PHULFD    
1RUWK$IULFD	0LGGOH(DVW    
2FHDQLD    
1RUWK$PHULFD    
6RXWK	6RXWK(DVW$VLD    
6XE6DKDUDQ$IULFD    
:HVWHUQ(XURSH    
2YHUDOO    
50
Table 19: How severely is HIV/AIDS currently affecting your recruitment and
training expenses?
&RXQWU\
6HULRXV
LPSDFW
6RPH
LPSDFW
0LQLPDO
LPSDFW
1R
UHVSRQVH
$OJHULD    
$QJROD    
$UJHQWLQD    
$XVWUDOLD    
$XVWULD    
%DKUDLQ    
%DQJODGHVK    
%HOJLXP    
%ROLYLD    
%RVQLDDQG+HU]HJRYLQD    
%RWVZDQD    
%UD]LO    
%XOJDULD    
&DQDGD    
&KDG    
&KLOH    
&KLQD    
&RORPELD    
&RVWD5LFD    
&URDWLD    
&\SUXV    
&]HFK5HSXEOLF    
'HQPDUN    
'RPLQLFDQ5HSXEOLF    
(FXDGRU    
(J\SW    
(O6DOYDGRU    
(VWRQLD    
(WKLRSLD    
)LQODQG    
)UDQFH    
*DPELD    
*HRUJLD    
*HUPDQ\    
*KDQD    
*UHHFH    
*XDWHPDOD    
+RQGXUDV    
+RQJ.RQJ    
+XQJDU\    
,FHODQG    
,QGLD    
,QGRQHVLD    
,UHODQG    
,VUDHO    
,WDO\    
-DPDLFD    
-DSDQ    
-RUGDQ    
.HQ\D    
.RUHD    
/DWYLD    
/LWKXDQLD    
/X[HPERXUJ    
0DFHGRQLD)<5    
0DGDJDVFDU    
0DODZL    
0DOD\VLD    
0DOL    
0DOWD    
0DXULWLXV    
0H[LFR    
0RURFFR    
0R]DPELTXH    
1DPLELD    
1HWKHUODQGV    
1HZ=HDODQG    
1LFDUDJXD    
1LJHULD    
1RUZD\    
3DNLVWDQ    
3DQDPD    
3DUDJXD\    
3HUX    
3KLOLSSLQHV    
3RODQG    
&RXQWU\
6HULRXV
LPSDFW
6RPH
LPSDFW
0LQLPDO
LPSDFW
1R
UHVSRQVH
3RUWXJDO    
5RPDQLD    
5XVVLDQ)HGHUDWLRQ    
6HUELD	0RQWHQHJUR    
6LQJDSRUH    
6ORYDN5HSXEOLF    
6ORYHQLD    
6RXWK$IULFD    
6SDLQ    
6UL/DQND    
6ZHGHQ    
6ZLW]HUODQG    
7DLZDQ    
7DQ]DQLD    
7KDLODQG    
7ULQLGDG	7REDJR    
7XQLVLD    
7XUNH\    
8JDQGD    
8NUDLQH    
8QLWHG$UDE(PLUDWHV    
8QLWHG.LQJGRP    
8QLWHG6WDWHV    
8UXJXD\    
9HQH]XHOD    
9LHWQDP    
=DPELD    
=LPEDEZH    
,QFRPHJURXSVXEWRWDO
/RZLQFRPH    
/RZHUPLGGOHLQFRPH    
8SSHUPLGGOHLQFRPH    
+LJKLQFRPH    
81$,'6+,9SUHYDOHQFHJURXSVXEWRWDO
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH!    
3UHYDOHQFHXQFODVVLILHG    
5HJLRQDOVXEWRWDO
&DULEEHDQ    
(DVW$VLD    
(DVWHUQ(XURSH	&HQWUDO$VLD    
/DWLQ$PHULFD    
1RUWK$IULFD	0LGGOH(DVW    
2FHDQLD    
1RUWK$PHULFD    
6RXWK	6RXWK(DVW$VLD    
6XE6DKDUDQ$IULFD    
:HVWHUQ(XURSH    
2YHUDOO    
51
Table 20: How severely is HIV/AIDS currently affecting your revenues?
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&DULEEHDQ    
(DVW$VLD    
(DVWHUQ(XURSH	&HQWUDO$VLD    
/DWLQ$PHULFD    
1RUWK$IULFD	0LGGOH(DVW    
2FHDQLD    
1RUWK$PHULFD    
6RXWK	6RXWK(DVW$VLD    
6XE6DKDUDQ$IULFD    
:HVWHUQ(XURSH    
2YHUDOO    
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Table 21: Does HIV/AIDS stigma and discrimination affect the effectiveness of
your policy and/or programme? (Including responses of companies not having
HIV/AIDS policies)
&RXQWU\
6HULRXV
LPSDFW
6RPH
LPSDFW
0LQLPDO
LPSDFW
1R
UHVSRQVH
$OJHULD    
$QJROD    
$UJHQWLQD    
$XVWUDOLD    
$XVWULD    
%DKUDLQ    
%DQJODGHVK    
%HOJLXP    
%ROLYLD    
%RVQLDDQG+HU]HJRYLQD    
%RWVZDQD    
%UD]LO    
%XOJDULD    
&DQDGD    
&KDG    
&KLOH    
&KLQD    
&RORPELD    
&RVWD5LFD    
&URDWLD    
&\SUXV    
&]HFK5HSXEOLF    
'HQPDUN    
'RPLQLFDQ5HSXEOLF    
(FXDGRU    
(J\SW    
(O6DOYDGRU    
(VWRQLD    
(WKLRSLD    
)LQODQG    
)UDQFH    
*DPELD    
*HRUJLD    
*HUPDQ\    
*KDQD    
*UHHFH    
*XDWHPDOD    
+RQGXUDV    
+RQJ.RQJ    
+XQJDU\    
,FHODQG    
,QGLD    
,QGRQHVLD    
,UHODQG    
,VUDHO    
,WDO\    
-DPDLFD    
-DSDQ    
-RUGDQ    
.HQ\D    
.RUHD    
/DWYLD    
/LWKXDQLD    
/X[HPERXUJ    
0DFHGRQLD)<5    
0DGDJDVFDU    
0DODZL    
0DOD\VLD    
0DOL    
0DOWD    
0DXULWLXV    
0H[LFR    
0RURFFR    
0R]DPELTXH    
1DPLELD    
1HWKHUODQGV    
1HZ=HDODQG    
1LFDUDJXD    
1LJHULD    
1RUZD\    
3DNLVWDQ    
3DQDPD    
3DUDJXD\    
3HUX    
3KLOLSSLQHV    
3RODQG    
&RXQWU\
6HULRXV
LPSDFW
6RPH
LPSDFW
0LQLPDO
LPSDFW
1R
UHVSRQVH
3RUWXJDO    
5RPDQLD    
5XVVLDQ)HGHUDWLRQ    
6HUELD	0RQWHQHJUR    
6LQJDSRUH    
6ORYDN5HSXEOLF    
6ORYHQLD    
6RXWK$IULFD    
6SDLQ    
6UL/DQND    
6ZHGHQ    
6ZLW]HUODQG    
7DLZDQ    
7DQ]DQLD    
7KDLODQG    
7ULQLGDG	7REDJR    
7XQLVLD    
7XUNH\    
8JDQGD    
8NUDLQH    
8QLWHG$UDE(PLUDWHV    
8QLWHG.LQJGRP    
8QLWHG6WDWHV    
8UXJXD\    
9HQH]XHOD    
9LHWQDP    
=DPELD    
=LPEDEZH    
,QFRPHJURXSVXEWRWDO
/RZLQFRPH    
/RZHUPLGGOHLQFRPH    
8SSHUPLGGOHLQFRPH    
+LJKLQFRPH    
81$,'6+,9SUHYDOHQFHJURXSVXEWRWDO
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH    
3UHYDOHQFH!    
3UHYDOHQFHXQFODVVLILHG    
5HJLRQDOVXEWRWDO
&DULEEHDQ    
(DVW$VLD    
(DVWHUQ(XURSH	&HQWUDO$VLD    
/DWLQ$PHULFD    
1RUWK$IULFD	0LGGOH(DVW    
2FHDQLD    
1RUWK$PHULFD    
6RXWK	6RXWK(DVW$VLD    
6XE6DKDUDQ$IULFD    
:HVWHUQ(XURSH    
2YHUDOO    
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Table 22: Does HIV/AIDS stigma and discrimination affect the effectiveness of
your policy and/or programme? (Only responses of companies at least having
informal policies)
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1 AIDS Epidemic Update 2004. UNAIDS, Geneva. 2004.
2 David E Bloom, Lakshmi Reddy Bloom, David Steven
and Mark Weston; Business and HIV/AIDS: Who Me?
World Economic Forum, 1 December 2003.
3 Haiti was included last year but not this year. Bahrain,
Bosnia and Herzegovina, Cyprus, Georgia and the United
Arab Emirates, meanwhile, have been added in 2004-
2005.
4 Income groups are defined according to World Bank
criteria as outlined in the 2004 World Development
Report. Low-income countries are defined as those that
had gross national income (GNI) per capita of US$ 735 or
less in 2003; lower middle-income as those with GNI per
capita between US$ 736 and US$ 2,935; upper middle-
income as those with GNI per capita between US$ 2,936
and US$ 9,075; and high-income as those with GNI per
capita of $9,076 and above.
5 HIV prevalence is grouped as per UNAIDS criteria.
High-prevalence countries have over 20% adult infection
rates, low prevalence below 1%. Intermediate groupings
are 1-4%, 5-9%, 10-14% and 15-19%.
6 Although there are many more annual cases of malaria
in African than there are new HIV infections
(approximately 270 million cases for malaria versus 3.2
million for HIV), HIV causes more deaths (2.3 million in
2003 versus 1.1 million for malaria). Roll Back Malaria
Information Sheet, World Health Organization. 2004.
Available at
http://www.rbm.who.int/cmc_upload/0/000/015/370/RB
MInfosheet_3.htm.
7 David E Bloom, Lakshmi Reddy Bloom, David Steven
and Mark Weston; Business and HIV/AIDS: Who Me?
World Economic Forum, Geneva. 1 December 2003.
8 This emphasis on fairness ties in with UNAIDS’ recent
exhortations to consider the “interplay” between gender
and socio-economic inequality in HIV prevention efforts.
UNAIDS (2004). op cit.
9 Note: The sample size for those firms in high-
prevalence countries that have conducted studies is 63,
and for those that have not, 108. 
10 This year’s regional groupings are different from those
in the 2003-2004 survey, so we have included only limited
discussion of year-on-year changes in this section. There
are now ten regions rather than eight and they have been
reclassified so that countries now match UNAIDS regional
groupings. The latter reflect pure geography, but with an
awareness of how HIV prevalence varies geographically
(for example, they separate Western and Eastern Europe).
Of the regions most affected by AIDS, only sub-Saharan
Africa is classified as it was last year. Comparisons over
time are made more problematic by the fact that
Executive Opinion Survey countries are not stable. For
example, Haiti was included last year but not this year.
Bahrain, Bosnia and Herzegovina, Cyprus, Georgia and
the United Arab Emirates, meanwhile, have been added
in 2004-2005.
11 This figure provides a policy coverage score for each
region. This score is calculated for each firm by summing
the number of policy dimensions that are addressed by
their HIV/AIDS policy. This information comes from
Question 7.27. The minimum value for PCS is 0, for a firm
that does not report addressing any of the policy
dimensions in Question 7.27. The maximum value is 16,
for a firm whose policy addresses every dimension. 
The figures reported are simple averages across all firms
in each corresponding income, prevalence, or regional
category. Thus, one standard issue that arises in creating
an index – that of having to assign weights to the various
dimensions – is addressed here by assigning equal
weight to each dimension. The other standard issue that
arises has to do with what to include. That is solved here
by including all 16 dimensions identified in Question 7.27. 
PCS is calculated using the whole sample (8,719 firms)
but assigns a PCS of zero to a firm that does not have a
written or informal HIV/AIDS policy, based on Question
7.24.
Note that the range of the PCS score goes from 0 to 16.
The score itself is the average number of policy
dimensions addressed by the sample of firms in the
relevant income, regional, or prevalence grouping. The
average PCS over all 8,719 firms is 1.33 (small number of
policy areas covered). The number is even smaller (0.73) if
0 is assigned to firms that say they have no written or
informal HIV/AIDS policy. However, for the 1,620 firms
that say they have a written or informal HIV/AIDS policy,
the average is 3.95.
12 The 1,552 firms that responded to the survey in sub-
Saharan Africa came from 19 countries: Angola,
Botswana, Chad, Ethiopia, Gambia, Ghana, Kenya,
Madagascar, Malawi, Mali, Mauritius, Mozambique,
Namibia, Nigeria, South Africa, Tanzania, Uganda, Zambia
and Zimbabwe. This list includes some of the hardest hit
countries in the world. Botswana, Namibia, South Africa
and Zimbabwe have over 20% HIV prevalence. Zambia
has over 15% prevalence. In Malawi and Mozambique,
infection rates exceed 10%, and in Kenya, Nigeria and
Tanzania 5%. Only in Mauritius have rates remained
below 1%. UNAIDS believes the epidemic’s spread in
Africa has slowed in recent years due to the growing
number of deaths. It remains, however, by far the worst
affected region in the world, with 2.3 million AIDS deaths
in 2003. UNAIDS, Geneva. 2004.
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13 See 10 above.
14 The 231 firms that responded to the survey in the
Caribbean came from three countries: Dominican
Republic, Jamaica and Trinidad & Tobago. HIV prevalence
in all three is between 1% and 4%. According to UNAIDS,
between 350,000 and 590,000 individuals in the region
are living with HIV/AIDS, with 30-50,000 deaths in 2003.
The response to the virus, it notes, has intensified in the
past year. UNAIDS, Geneva. 2004.
15 The 562 firms that responded to the survey in East
Asia came from five countries: China, Hong Kong, Japan,
Korea and Taiwan. HIV prevalence rates in all bar Taiwan
are below 1%. The prevalence rate in Taiwan is unknown.
16 The 1,795 firms that responded to the survey in
Eastern Europe and Central Asia came from 16 countries:
Bosnia and Herzegovina, Bulgaria, Croatia, Czech
Republic, Estonia, Georgia, Hungary, Latvia, Lithuania,
Poland, Romania, Russian Federation, Serbia &
Montenegro, Slovak Republic, Slovenia and Ukraine. Of
these, Estonia, Russian Federation and Ukraine have HIV
prevalence rates between 1% and 4%, while the rest
have rates below 1%. Between 1.2 million and 1.8 million
people in the region are believed to be infected with the
virus, although since AIDS is still relatively new to the
area, the number of deaths (approximately 30,000 in
2003) is lower than other middle- and low-income
regions. UNAIDS reports encouraging efforts by many
Eastern European and Central Asian countries to tackle
the disease. UNAIDS, Geneva. 2004.
17 The 1,430 firms that responded to the survey in Latin
America came from 17 countries: Argentina, Bolivia,
Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador,
Guatemala, Honduras, Mexico, Nicaragua, Panama,
Paraguay, Peru, Uruguay and Venezuela. All of these bar
Guatemala and Honduras, where rates are between 1%
and 4%, have HIV prevalence below 1%. UNAIDS reports
that 1.3-1.9 million Latin Americans are living with the
virus, with 49-70,000 deaths in 2003. The region’s most
affected countries, it adds, have begun to respond
effectively to the disease in recent years, with increased
national HIV/AIDS budgets and half of those who need
anti-retroviral therapy receiving it. UNAIDS, Geneva. 2004.
18 The 918 firms that responded to the survey in North
Africa and the Middle East came from 10 countries:
Algeria, Bahrain, Cyprus, Egypt, Israel, Jordan, Morocco,
Tunisia, Turkey and the United Arab Emirates. All of these
bar Cyprus have HIV prevalence below 1%. The
prevalence rate in Cyprus is unknown. UNAIDS believes
that, although HIV prevalence is “very low” in the region,
with 600,000 people already infected (and 45,000 deaths
in 2003) and a so far limited response, there is potential
for a “considerable rise” in infection rates.
19 The 752 firms that responded to the survey in South
and South-East Asia came from 10 countries:
Bangladesh, India, Indonesia, Malaysia, Pakistan,
Philippines, Singapore, Sri Lanka, Thailand and Vietnam.
Thailand has HIV prevalence rates between 1% and 4%,
with all the rest below 1%. The epidemic has so far been
largely confined to vulnerable groups such as sex workers
and injecting drug users. The region’s huge populations,
however, mean that low prevalence rates do not mean
low numbers of infections – UNAIDS estimates that
between 4.6 and 8.2 million individuals are infected even
though adult prevalence rates may be as low as 0.4%.
With over 600,000 new infections in 2003, moreover,
there is potential for dramatic growth if governments fail
to respond to the problem. Between 330,000 and
590,000 people are thought to have died of the disease
in 2003. UNAIDS, Geneva. 2004.
20 “Other” includes agriculture, fishing, mining and
quarrying, electricity, gas and water supply, hotels and
restaurants, real estate and renting, public administration
and defence, education, health and social work, other
community services, private household employers, extra-
territorial organizations, “unclassifiable” and “missing”.
21 Some caveats are in order here. Two years’ data
cannot demonstrate clear trends, particularly given the
short time between surveys relative to the time it can take
to develop policies or programmes. Additionally, some
questions in the survey have been changed. Most
importantly, the samples are not strictly comparable.
African firms make up a slightly lower proportion of this
year’s sample, and there are marginally fewer firms from
low-income countries and slightly more from lower
middle-income and high-income countries. There are also
significantly more firms from countries with 1-4% national
HIV prevalence rates – they comprise 19% of the sample
this year, compared to 12% last year. The proportion of
firms in the 5-9% prevalence group, meanwhile, has fallen
from 8% to 5%. Finally, the 15-19% prevalence group
was made up of firms from Kenya and Malawi in 2003-
2004. This year, those countries’ infection rates have
declined, leaving Zambia, whose own rates have declined
from above 20%, as the only country represented in the
15-19% prevalence group. Year-on year comparisons
should not therefore be seen as hard and fast indicators
of concrete change, but as a guide to how opinions and
policies may be evolving. 
22 Last year, firms were asked a single question on the
current and future impact of HIV/AIDS. This year, they
were asked two separate questions (one current, one
future). Figure 10 combines responses to these two
questions for this year.
23 Four countries showed a double-digit increase in
serious concern over the virus between 2003-04 and
2004-05. They were Indonesia (up from 13% to 28%),
Poland (3% to 16%), El Salvador (8% to 19%), Guatemala
(8% to 18%). 16 countries showed double-digit declines
in concern. They were Vietnam (down from 74% to 18%),
Mali (54% to 26%), Ghana (55% to 30%), South Africa
(79% to 56%), Ethiopia (72% to 51%), Morocco (30% to
13%), Ukraine (22% to 5%), Nigeria (46% to 31%),
Zimbabwe (94% to 80%), Trinidad & Tobago (48% to
35%), Jamaica (53% to 41%), China (25% to 13%),
Nicaragua (23% to 11%), Kenya (63% to 52%), Tunisia
(15% to 4%) and Angola (38% to 28%).
24 Last year, respondents were asked whether their
estimates were based on a quantitative study including
company-specific information. This year they were asked
if the estimate was based on a quantitative HIV/AIDS risk
assessment, and the “don’t know” option was listed first
among the possible responses.
25 Last year’s questionnaire gave respondents the option
of indicating whether their policies were approved by the
board, unions or company health committees. This year’s
survey only gives three options: no policy, an informal
policy (in that other policies include HIV/AIDS-related
components) or a written HIV/AIDS-specific policy. Only
written policies can therefore be compared, and these
only with caution given the difference in the way the
question was asked in the two surveys.
26 For background on The Global Competitiveness
Report and the Executive Opinion Survey, see Appendix
2.
27 David E Bloom, Lakshmi Reddy Bloom, David Steven
and Mark Weston; Business and HIV/AIDS: Who Me?
World Economic Forum, Geneva. 1 December 2003.
28 As is typical for such a survey, the response rate was
low and makes the data vulnerable to potential biases.
However, they do correspond closely with other surveys
of business executives with higher response rates.
29 http://www.weforum.org/pdf/Gcr/
Executive_Summary_GCR_04
30 The Global Competitiveness Report 2004; World
Economic Forum.
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